CA2034741C - Therapeutic antibody based fusion proteins - Google Patents
Therapeutic antibody based fusion proteins Download PDFInfo
- Publication number
- CA2034741C CA2034741C CA002034741A CA2034741A CA2034741C CA 2034741 C CA2034741 C CA 2034741C CA 002034741 A CA002034741 A CA 002034741A CA 2034741 A CA2034741 A CA 2034741A CA 2034741 C CA2034741 C CA 2034741C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- fusion protein
- fusion proteins
- tumor
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
Abstract
The present invention relates to a system for the generation of antibody fusion proteins which has utility in the production of recombinant molecules that possess novel, clinically relevant biological activity. The antibody fusion proteins of the invention may be used therapeutically to deliver biologically active ligands to a desired tissue.
In particular embodiments of the invention, the antibody fusion protein comprises a biologically active ligand which is a lymphokine, including, in a specific embodiment, interleukin-2. Because interleukin-2 induces lymphocyte proliferation, fused antibody that targets interleukin-2 (IL-2) to a malignant or infected tissue can produce localized amplification of the immune response toward the diseased tissue, and thereby facilitate the destruction of the infected or malignant tissue. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active IL-2.
Additional embodiments of the invention relate to fused antibodies which comprise an immunoglobulin variable region and a biologically active ligand which is a-non-lymphokine cellular factor. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active platelet factor 4, a molecule associated with antagonism of angiogenesis, inhibition of suppressor T lymphocyte development, chemotaxis and heparin binding.
In particular embodiments of the invention, the antibody fusion protein comprises a biologically active ligand which is a lymphokine, including, in a specific embodiment, interleukin-2. Because interleukin-2 induces lymphocyte proliferation, fused antibody that targets interleukin-2 (IL-2) to a malignant or infected tissue can produce localized amplification of the immune response toward the diseased tissue, and thereby facilitate the destruction of the infected or malignant tissue. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active IL-2.
Additional embodiments of the invention relate to fused antibodies which comprise an immunoglobulin variable region and a biologically active ligand which is a-non-lymphokine cellular factor. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active platelet factor 4, a molecule associated with antagonism of angiogenesis, inhibition of suppressor T lymphocyte development, chemotaxis and heparin binding.
Description
~i ,,; j r~ .~ .
1. INTRODUCTION
The present invention relates to antibody based proteins in which a portion of an antibody is fused to a biologically active ligand. The resulting fusion protein may be used to deliver the active molecule to a specific 5target cell or tissue. In particular embodiments of the present invention, a portion of an antibody which recognizes a tumor cell is linked to a ligand which is an antitumor agent. In a preferred embodiment of the present invention, a portion of an antibody which recognizes a tumor cell is ~Olinked to a lymphokine such as IL-2, thereby providing a method for producing a targeted, amplified anti-tumor immune response.
1. INTRODUCTION
The present invention relates to antibody based proteins in which a portion of an antibody is fused to a biologically active ligand. The resulting fusion protein may be used to deliver the active molecule to a specific 5target cell or tissue. In particular embodiments of the present invention, a portion of an antibody which recognizes a tumor cell is linked to a ligand which is an antitumor agent. In a preferred embodiment of the present invention, a portion of an antibody which recognizes a tumor cell is ~Olinked to a lymphokine such as IL-2, thereby providing a method for producing a targeted, amplified anti-tumor immune response.
2. BACKGROUND of THE INVENTION
'S 2.1. MONOCLONAL ANTIBODIES AS DIAGNOSTIC
AND THERAPEUTIC REAGENTS
Since the development of the cell fusion technique for the production of monoclonal antibodies (Kohler and Milstein, 1975, Nature 256:495), a vast number 20 of monoclonal antibodies, many of which define heretofore unknown antigens, have been produced by a number of researchers. Concurrently, a number of techniques have been developed for the generation of monoclonal antibodies, including the B cell hybridoma technique (Kozbor et al, 25 1983, Immunology Today 4:72) and the EBV hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in "Monoclonal Antibodies and Cancer Therapy," Alan R. Liss, Inc. pp. 77-96).
Through hybridoma technology, monoclonal ~ antibodies (Mab) can be developed that are capable of recognizing almost any determinant or epitope. The property of specific recognition and binding to particular cells has encouraged the development of Mabs as diagnostic and thera-peutic reagents fox a variety of disease states. Mabs have '~ 7~ '~ ii ~i :7 'i -4- ~d ~: .
been obtained that recognize determinants preferentially expressed on tumor cells (Hellstrom et al., 1984 in ''Monoclonal Antibodies and Cancer", Wright et. al. Marcel Dekker, Inc., N.Y., pp. 31-47) and are currently being evaluated in the clinic for their effectiveness as therapeutic agents.
2.2. USE OF MONOCLONAL ANTIBODIES AS
TARGETING AGENTS
The ability of monoclonal antibodies (blabs) to localize to tumor tissue has also led to the development of blabs conjugated to various substances in an effort to target specific molecules to tumor sites (Hellstrom and Hellstrom, 1985, in "Monoclonal Antibodies for Tumor Detection and Drug Targeting," Baldwin et al. eds, Academic Press, N.Y. pp.
17-51). Linkages have been performed using toxins, drugs, radionuclides, and enzymes for the activation of prodrug compounds. Many of these linkages involve the chemical conjugation of the reactive moiety with a given preparation of antibody, a process which can be cumbersome and subject to variation. (U. S. Patent No. 4,671,958 by Rodwell et al., filed March 9, 1982, issued June 9, 1987).
Recently, recombinant DNA techniques have been used to produce genetically altered immunoglobulin molecules. For example, techniques have been developed to 2b produce chimeric antibodies, which combine regions of immunoglobulin molecules from different sources (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6581; Sahagan et al., 1986, J. Immunol. 137:1066; Sun et al., 1987, Proc.
Natl. Acad. Sci. U.S.A. 84:214). Usually, chimeric ~ antibodies combine an antigen=combining region (or variable region) from a non-human source and a constant region from a human source., Chimeric antibody technology has been extended to produce chimeric molecules comprising immunoglobulin and non-immunoglobulin portions. For example, International Patent Application No.
PCT/GB85/00392 by Neuberger et al., filed September 3, 1985, and published March 13, 1986, describes the production of Fab-Staphylococcus aureus nuclease, Fab-myc, and Fab-Klenow fragment of DNA polymerise I chimeric antibodies (see also Neuberger et al., 1984, Nature 312:604-608 and Williams and Neuberger, 1986, Gene 43:319-324). Schnee et al. (1987, Proc. Natl. Acid. Sci.
U.S.A. 84:6904-6908) describe the construction of a hybrid molecule comprising the variable region of an anti-fibrin antibody and the catalytic ~i-chain of tissue plasminogen activator.
'S 2.1. MONOCLONAL ANTIBODIES AS DIAGNOSTIC
AND THERAPEUTIC REAGENTS
Since the development of the cell fusion technique for the production of monoclonal antibodies (Kohler and Milstein, 1975, Nature 256:495), a vast number 20 of monoclonal antibodies, many of which define heretofore unknown antigens, have been produced by a number of researchers. Concurrently, a number of techniques have been developed for the generation of monoclonal antibodies, including the B cell hybridoma technique (Kozbor et al, 25 1983, Immunology Today 4:72) and the EBV hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in "Monoclonal Antibodies and Cancer Therapy," Alan R. Liss, Inc. pp. 77-96).
Through hybridoma technology, monoclonal ~ antibodies (Mab) can be developed that are capable of recognizing almost any determinant or epitope. The property of specific recognition and binding to particular cells has encouraged the development of Mabs as diagnostic and thera-peutic reagents fox a variety of disease states. Mabs have '~ 7~ '~ ii ~i :7 'i -4- ~d ~: .
been obtained that recognize determinants preferentially expressed on tumor cells (Hellstrom et al., 1984 in ''Monoclonal Antibodies and Cancer", Wright et. al. Marcel Dekker, Inc., N.Y., pp. 31-47) and are currently being evaluated in the clinic for their effectiveness as therapeutic agents.
2.2. USE OF MONOCLONAL ANTIBODIES AS
TARGETING AGENTS
The ability of monoclonal antibodies (blabs) to localize to tumor tissue has also led to the development of blabs conjugated to various substances in an effort to target specific molecules to tumor sites (Hellstrom and Hellstrom, 1985, in "Monoclonal Antibodies for Tumor Detection and Drug Targeting," Baldwin et al. eds, Academic Press, N.Y. pp.
17-51). Linkages have been performed using toxins, drugs, radionuclides, and enzymes for the activation of prodrug compounds. Many of these linkages involve the chemical conjugation of the reactive moiety with a given preparation of antibody, a process which can be cumbersome and subject to variation. (U. S. Patent No. 4,671,958 by Rodwell et al., filed March 9, 1982, issued June 9, 1987).
Recently, recombinant DNA techniques have been used to produce genetically altered immunoglobulin molecules. For example, techniques have been developed to 2b produce chimeric antibodies, which combine regions of immunoglobulin molecules from different sources (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6581; Sahagan et al., 1986, J. Immunol. 137:1066; Sun et al., 1987, Proc.
Natl. Acad. Sci. U.S.A. 84:214). Usually, chimeric ~ antibodies combine an antigen=combining region (or variable region) from a non-human source and a constant region from a human source., Chimeric antibody technology has been extended to produce chimeric molecules comprising immunoglobulin and non-immunoglobulin portions. For example, International Patent Application No.
PCT/GB85/00392 by Neuberger et al., filed September 3, 1985, and published March 13, 1986, describes the production of Fab-Staphylococcus aureus nuclease, Fab-myc, and Fab-Klenow fragment of DNA polymerise I chimeric antibodies (see also Neuberger et al., 1984, Nature 312:604-608 and Williams and Neuberger, 1986, Gene 43:319-324). Schnee et al. (1987, Proc. Natl. Acid. Sci.
U.S.A. 84:6904-6908) describe the construction of a hybrid molecule comprising the variable region of an anti-fibrin antibody and the catalytic ~i-chain of tissue plasminogen activator.
3. SUMMARY OF THE INVENTION
The present invention relates to a system for the generation of antibody fusion proteins which has utility in the production of recombinant molecules that possess novel, clinically relevant biological activity. The antibody fusion proteins of the invention may be used therapeutically to deliver biologically active ligands to a desired tissue.
In an embodiment of the invention there is provided an antibody-based fusion protein. The antibody-based fusion protein comprises a portion of an immunoglobulin molecule capable of directing the fusion protein to a tumor cell or a tumor associated antigen, and an interleukin-2 molecule capable of promoting lymphocyte proliferation.
In an embodiment of the invention there is provided the use of an antibody-based fusion protein comprising a portion of an immunoglobulin molecule capable of directing the fusion protein to a tumor cell or a tumor associated antigen and an interleukin-2 molecule capable of promoting lymphocyte proliferation to increase an anti-tumor response.
In an embodiment of the invention there is provided the use of an antibody-based fusion body protein comprising a portion of an immunoglobulin molecule capable of directing the fusion protein to a tumor cell or a tumor associated antigen, and an interleukin-2 molecule capable of promoting lymphocyte proliferation, in the preparation of a medicament useful to increase an -Sa-anti-tumor immune response.
In an embodiment of the invention there is provided use of an antibody-based fusion body protein comprising a portion of an immunogtobulin molecule capable of directing fusion protein to a tumor cell or a tumor associated antigen, and an interleukin-2 molecule capable of promoting lymphocyte proliferation in the preparation of a medicament useful to increase an anti-tumor immune response.
In particular embodiments of the invention, the antibody fusion protein comprises a biologically active ligand which is a lymphokine, including, in a specific embodiment, interleukin-2. Because interleukin-2 induces lymphocyte proliferation, fused antibody that targets interleukin-2 (IL-2) to a malignant or infected tissue can product localized amplification of the immune response toward the diseased tissue, and thereby facilitate the destruction of the infected or malignant tissue. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active II-2.
Additional embodiments of the invention relate to fused antibodies which comprise an immunoglobulin variable region and a biologically active ligand which is a non-lymphokine cellular factor. In a specific embodiment of the »; , e: i ~') ~a 1, - "~
invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active platelet factor 4, a molecule associated with antagonism of angiogenesis, .inhibition of suppressor T lymphocyte development, chemotaxis and heparin x>inding.
DESCRIPTION OF THE FIGURES
Figure 1. Diagram of insertion of CH1 into pUCl8 vector.
Figure 2. Diagram of insertion of PF-4 cDNA into CHl, Hinge-Bearing Vector.
Figure 3. Diagram of insertion of construct into a mammalian expression vector.
Figure 4. Production of PF-4/L6 fusion protein by cell lines transfected with PF-4/L6 expression vector, as measured by reactivity with anti-L6 idiotype antibody.
Figure 5. Inhibition of binding of anti-PF-4 antibody to PF-~/L6 fusion protein by increasing concentrations of free PF-4.
Figure 6. Diagram of strategy for the generation of IL-2/L6 20 fusion proteins. (a) insertion of IL-2 cDNA into pUCl8 vector containing CH1 amd 3' untranslated regions (3'uT) from the mouse immunoglobulin gene locus with incorporation of hinge/linker sequences; (b) final expression vector comprising SV40ori promoter and the 25 neo resistance gene.
Figure 7. Exact hinge (a) and hinge-linker (b) sequences.
Figure 8. Procedure of producing IL-2 cDNA for cloning.
Figure 9. Coding portion of IL-2 amplified in polymerase chain reaction.
~ Figure 10. Chimeric light chain vector cotransfected with pIL-2/L6 .
s'~ ; a r~ .? .~
Y.,I '. ~~
5. DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a system for the generation of therapeutic antibody fusion proteins. In particular, the present invention relates to therapeutic antibody fusion proteins as well as the recombinant DNA
5molecules utilized in their production. For purposes of clarity of disclosure, and not by way of limitation, the detailed description of the invention will be divided into the following subsections:
(i) construction of recombinant genes encoding antibody fusion proteins;
(ii) expression of antibody fusion proteins; and (iii) utility of the invention.
5.1. CONSTRUCTION OF RECOMBINANT GENES
The antibody-based fusion proteins of the invention comprise (i) a portion of an immunoglobulin ...:,lecule capable of directing the fusion protein to an intended cell or tissue and (ii) a biologically active 20protein or peptide. The recombinant genes encoding the antibody fusion proteins of the invention may be constructed using any technique known in the art of molecular biology, including but not limited to the following.
The targeting portion of the molecule may 25comprise all ar part of an immunoglobulin variable region which.may, in turn, be comprised of regions encoded by a V
gene and/or D gene and/or J gene. In preferred embodiments of the inventian, the antibody fusion proteins comprise a portion corresponding to the hinge region of an ~immunoglobulin molecule, or a functional equivalent thereof which would provide flexibility between the globular domains of the antibody-based fusion protein. A functional hinge may be important in retaining targeting ability. Variable regions of antibody, particularly monoclonal antibody, that ~
',; ; : ; j r'.f ? 1 (.~ '' .. ..
-g-recognize tumor-specific antigens, viral-specific antigens, bacterial antigens, parasite antigens, or antigens expressed on a particular population of cells (such as lymphocytes) may be used in fusion proteins of the invention.
Ligands which may be incorporated into the antibody-based fusion proteins of the invention include but are not limited to lymphokines and cellular factors which interact with specific cellular receptor. Lymphokines of the invention include but are not limited to interleukin-1 (Henderson and Pettipher, 1988, Biochem. Pharmacol.
~B 37:4717); interleukin-2 (Weil-Hillman et al., 1988, J. Biol.
Response Mod. 7:424); interleukin-6 (Van Damme et al., 1987, J. Exp. Med. 165:914-919); interferon a (Piths et al., 19898, J. Immunol. 141:3611): and interferon y (Blanchard and Djeu, 1988, J. Immunol. 141:4067).
Cellular factors which may be incorporated into the antibody-based fusion proteins of the invention include but are not limited to platelet factor 4 (bevel et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:4584-4587): tumor necrosis factor a (Plate et al, 1988, Ann. N.Y. Acad. Sci.
2Q 532:149); epidermal growth factor (carpenter arid Cohen, A.
Rev. Biochem. 48:193-216): fibroblast growth factor (Folkman and Klagsburn, 1987, Science 235:442-447): insulin-like growth factor-1 (Blundell and Humbel, 1980, Nature 287:781-787); insulin-like growth factor-2 (Blundell and Humbel, 25 supra) platelet-derived growth factor (Ross et al., 1986, Cell 46:155-169); transforming growth factor a (Derynck, 1988, Cell 54:593-595)p transforming growth factor ~
(Cheifetz et al., 1987, Cell 48:409-416): interferon ~ and nerve growth factor (Thoenen et al., 1982, in "Repair and ~ Regeneration of the Nervous System", J.G. Nicholls, ed., Springer-Verlag, NY, pp. 173-185).
Recombinant nucleic acid molecules which encode the immunoglobulin, lymphokine or growth factor may be ~ obtained by any method known in the art (Maniatis et al., r't ~..~ ~~ ~ 'i ~1 _g_ 1982, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) or obtained from publicly available clones. For example, nucleic acid encoding a lymphokine or factor may be obtained as follows.
A population of cells known to actively express the factor smay be obtained, and total cellular RNA may be harvested therefrom. Amino acid sequence of the factor may be used to deduce the sequence of a portion of the factor's nucleic acid so as to design appropriate oligonucleotide primers, or, alternatively, the oligonucleotide primers may be t0obtained from a known nucleic acid sequence which encodes the factor. The oligonucleotide fragment may then be used in conjunction with reverse transcriptase to produce cDNA
corresponding to factor-encoding nucleotide sequence (Okayama et al., 1987, Methods Enzymol. 154:3-29). The cDNA
~5can then be cloned, and/or portions of the factor coding region may then be amplified from this cDNA using polymerase chain reaction and appropriate primer sequences, (Saiki et al., 1988, Science 239:487-491).
In particular embodiments of the invention, a ZOrecombinant vector system may be created to accommodate sequences encoding the ligand in the correct reading frame with a natural or synthetic hinge region. For example, and not by way of limitation, the hinge region of the human IgGl constant region may be used: in a specific embodiment of the ZSinvention, the constant region axon encoding the CHl domain of human IgGl may be cloned as a HindIII-PstI fragment into the vector pUClB to which may be joined, using standard restriction enzyme techniques, a modified version of the human hinge region sequences of human IgGl. In the modified version of the human hinge region, the two cysteine residues that normally mediate interchain disulfide linkage may be replaced by codons specifying proline and serine so as to permit greater flexibility in the fused molecule: in this ~~ t3 ~i ,i ;
_1~_ s.e ' specific embodiment the sequence of the hinge region may be EF~KS CDKTHTPPPS PGRWGGRA .
Additionally, it may be desirable to include, as part of the recombinant vector system, nucleic acids corresponding to the 3' flanking region of an immunoglobulin 5ge:ne including RNA cleavage/polyadenylation sites and downstream sequences; according to a specific embodiment of the invention, this nucleotide sequence provides the mRNA
with the 3' untranslated region of the secretory form of the murine C~ gene. Furthermore, it may be desirable to ~~engineer a signal sequence upstream of the antibody fusion protein-encoding sequences to facilitate the secretion of the fused molecule from a cell transformed with the recombinant vector.
Nucleic acid sequences encoding the various i5components of the antibody-based fusion proteins of the invention may be joined together using any techniques known in the art, including restriction enzyme methodologies and the use of synthetic linker sequences.
To provide for adequate transcription of the 2precombinant constructs of the invention, a suitable promoter/enhancer sequence may preferably be incorporated into the recombinant vector. Promoters which may be used to control the expression of the antibody-based fusion protein include, but are not limited to, the SV40 early promoter 25region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3° long terminal repeat of Rous sarcoma virus (Yamamota, st al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc.
~Natl. Acad. Sci. U.S.A. 78:144-1445), the regulatory sequences of the metallothionine gene (Brinster et al., 1982, Nature 296:39-42): prokaryotic expression systems such as the LAC, or ~-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac ~a phage promoter (DeBoer, et al., 1983, Proc. Natl. Acad.
Sci. U.S.A. 80:21-25), see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; plant expression vectors comprising the nopaline s;~nthetase promoter region (Herrera-Estrella et al., Nature _30_3:209-213) or the cauliflower mosaic virus 35S RNA promoter s(Gardner, et al., 1981, Nucl. Acids Res. 9:2871), and the promoter for the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310:115°
120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK
~D(phosphoglycerol kinase) promoter, alkaline phophatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et ~5a1., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515)p insulin gene enhancers or promoters which are active in pancreatic beta sells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene enhancers or 20promoters which are active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658: Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol.
7:1436-1444), the cytomegalovirus early promoter and enhancer regions (Boshart et al., 1985, Cell _41:521-530), mouse 2Smammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel.
X1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol.
5:1639-1648: Hammer et al., 1987, Science 235:53-58): alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al, 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid / . a J :1 F,.,~ .5 '( cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712): myosin light chain-2 gene control region which is active in skeletal 5muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).
Successful incorporation of antibody-based fusion gene constructs may be identified by three general 1~ approaches: (a) DNA-DNA hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising sequences ~5 that are homologous to the inserted antibody fusion protein gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e. g., thymidine kinase activity, resistance to antibiotics such as 20 6418, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the antibody fusion gene is inserted so as to interrupt the marker gene sequence of the vector, recombinants containing the antibody fusion gene 25 insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be ~ based, for example, on the physical or functional properties of the antibody fusion gene product in bioassay systems as described infra.
Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may ~ be used to propagate it. Once a suitable host system and -1.3- '3 ;: ;i ''~ '~
y ,. ,:, . . . : : ...
growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be ua;ed include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as 5vaccinia virus, adenovirus or retroviral based vectors;
insect viruses such as baculovirus; yeast vectors:
bacteriophage vectors (e. g., lambda), and plasmid and cosmid DNA vectors, to name but a few.
In a preferred embodiment of the invention, the ~~promoter/enhancer and 3' regulatory sequences may all be derived from immunoglobulin genes.
5.2. EXPRESSION OF ANTIBODY FUSION PROTEINS
The recombinant constructs of the invention may ~5be introduced into host cells which are capable of expressing the antibody-based fusion protein using any method known in the art, including transformation (for example, using DEAF-dextran or calcium phosphate techniques), transfection, microinjection, infection, cell 20gun, and electroporation. Any host cell type may be utilized provided that the antibody-based fusion protein recombinant nucleic acid sequences would be adequately transcribed into mRNA in that cell type. In specific embodiments of the invention, mouse myeloma cell lines which ?5~o not produce immunoglobulin, such as Sp2/o or Ag8.653 may b~~ used. In addition, the recombinant nucleic acid constructs of the invention may be used to create non-human transgenic animals capable of producing the antibody based fusion protein. 3n preferred embodiments of the invention, the host cell is a lymphoid call. In specific embodiments of the invention, the host cell is a hybridoma derived heavy chain loss variant which expresses immunoglobulin light chains: in this embodiment, the parent hybridoma most preferably may be the source of the monoclonal antibody which comprises the immunoglobulin portions of the antibody-based fusion protein. Thus, for example, and not by way of limitation, the light-chain producing cell line derived from a hybridoma which produces monoclonal antibody "X" may be transfected with recombinant DNA encoding an antibody-based fusion protein which comprises a variable region of monoclonal antibody "X" ; the antibody-based fusion protein may combine with endogenous light chain and thereby re-create the antigen binding site of monoclonal antibody "X" .
Alternatively, recombinant nucleic acids encoding both antibody-based fusion protein and corresponding or compatible immunoglobulin light chain may be cotransfected into a cell line which is preferably of lymphoid origin. In yet a further embodiment of the invention, the antibody fusion protein encoding sequences may be introduced into the immunoglobulin locus of a lymphoid cell line by homologous recombination.
Antibody-based fusion protein produced by the host cell may be collected using any technique known in the art, including, but not limited to, affinity chromatography using target antigen or antibody specific for any portion of the fusion protein including, for example, anti-idiotype antibody. The activity of the fused lymphokine or cellular factor may be confirmed using biological assays which detect or measure the activity of the lymphokine or cellular factor. For example, and not by way of limitation, if IL-2 is the lymphokine comprised by the antibody fusion protein, the presence of IL-2 activity may be confirmed in assays which detect T-cell proliferation. In a specific embodiment of the invention, the presence of PF4 activity is confirmed by observing that the antibody fusion protein binds to anti-PF4 antibody in a manner which is competitively inhibited by free, unconjugated PF4 protein.
The present invention provides for dimeric immunoglobulin molecules as well as monomeric or multimeric molecules comprising antibody based fusion proteins.
5.3. UTILITY OF THE INVENTION
The present invention provides for antibody based fusion proteins that may be used to deliver biologically active ligand molecules to specific target cells or tissues. In particular embodiments of the invention, the antibody fusion proteins comprise ligands which are lymphokines or other cellular factors.
In various embodiments of the invention, an antibody fusion protein may comprise variable region sE:quences which recognize a tumor specific antigen.
According to a specific embodiment of the invention, the variable region sequences are derived from L6, a monoclonal antibody which reacts with an antigen present on human non-small cell lung carcinoma and a number of other carcinomas, including breast and colon carciinoma (ATCC Accession Number HB 8677). If the antibody fusion molecule which recognizes a tumor specific antigen also comprises a lymphokine, it may be used to alter the immune response in the area of the tumor cells. For example, as shown in Example Section 7, infra, an antibody fusion protein comprising IL-2 and the IL6 variable region retains IL-2 activity. The fusion protein may be used to target IL-2 to tumor cells; consequently, activated T-cells in the vicinity of the tumor will be induced to proliferate, thereby amplifying the anti-tumor immune response. It should be noted that current immunotherapy often involves systemic administration of lymphokines at a concentration that is intended to effectively boost anti-tumor activity but which necessarily affects lymphocytes and tissues throughout the body. In the case of IL-2, severe -16- ~ f' and potentially fatal clinical reactions may occur. The present invention offers the advantage of decreasing systemic exposure to lymphokine; antibody-mediated targeting allows for less total lymphokine to be administered and 5substantially decreases the exposure of non-tumor tissues to lymphokine, thereby minimizing toxic effects. In a further specific embodiment, a PF4/L6 antibody may be used to inhibit angiogenesis at a tumor site and thereby inhibit tumor growth.
In additional embodiments, the antibady fusion 'oproteins of the invention may be directed toward antigens associated with infectious agents, including viral, bacterial, or parasitic antigens. In a specific embodiment, the antibody fusion protein may comprise a chemotactic factor which may be used to recruit polymorphonuclear ~5leukocytes to sites of infection, including the walls of abscesses.
Alternatively, the antibody fusion proteins of the invention may be directed toward antigens present on a subpopulation of cells in the body. For example, antibody 2~fusion proteins directed toward antigens on the surface of helper T-cel~.s could be used to target ligands which augment helper cell activity in immune compromised patients or to target ligands that down regulate T-helper responses in cases of autoimmunity. Alternatively, antibody fusion 25proteins directed toward antigens on the surface of suppressor T-cells may be used to regulate activity.
Subpopulations of cells could also be targeted based on receptor specificity (e. g. antigen for lymphocytes).
In additional embodiments of the invention, cellular factors that relate to wound healing may be incorporated into antibody fusion proteins. For example, fibroblast growth factor may be combined with an antibody ' which recognizes an antigen exposed by or applied to an area ~ of cell injury.
~~°~1.'?;5.
--17_ , The antibody fusion proteins may be administered to a patient in need of such treatment in any sterile pharmaceutical carrier which will maintain the solubility and activity of the protein. It may be desirable to administer antibody fusion proteins in conjunction with Bother treatment modalities, including antibodies and/or antibody fusion proteins comprising additional growth factors.
6. EXAMPLE: CONSTRUCTION AND EXPRESSION OF
6.1. MATERIALS AND METHODS
6.1.1. CONSTRUCTION OF AN EXPRESSION CASSETTE
FOR AN ANTIBODY-BASED FUSION PROTEIN
A recombinant vector system was created to 'Saccommodate sequences encoding novel protein structure in the correct reading frame with the hinge region of the human IgGl constant region. Initially,'the constant region axon encoding the CHl domain of human IgG1 was cloned as a HindIII/PstI fragment into the vector pUCl8 (Fig. 1).
Z~Downstream of these sequences was cloned a 1.6 kb Pstl/KpnI
fragment containing a portion of the 3' flanking region of the murine C~ gene that includes the RNA cleavage/
polyadenylation sites used in the expression of mRNA
encoding the secretory form of IgM heavy chain. A portion c ~~'of the vector polylinker was retained between the two fragments for subsequent additions.
A pair of oligonucleotides was generated that when annealed encode a modified version of the human hinge ~ region sequences of human IgGl: The two cysteines that normally mediate interchain disulfide linkage between heavy chains were replaced with codons specifying proline and serine, and several amino acids were added to the carboxy terminus such that the entire hinge region sequence is:
~EPKSCDKTHTPPPSPGRWGGRA. The annealed oligonucleotide pair i ~ J~~ F/ cj ~_ has a PstI compatible overhang on the 5' end, includes the rnormal splice acceptor site for the hinge axon, and retains another suitable overhang for linkage with additional oligonucleotides at the 3' end. A second pair of oligonucleotides was designed to overlap with the first set s and provide compatible ends for ligation with an NcoI
overhang.
6.1.2. INSERTION OF PLATELET FACTOR 4 ENCODTNG
SEQUENCES INTO ANTIBODY FUSION PROTEIN
CASSETTE
The cDNA clone encoding human platelet factor 4 (PF4) was linked as an NcoI/Baml fragment in frame with the hinge region by ligation into the PstI/BamI sites of the vector with the two pairs of oligonucleotides at the 5' end ~5(Fig. 2). The fusion construct was then transferred to a vector that contains a dominant selectable marker (NEO) for expression in mammalian cells (Fig. 3), and then a gene segment encoding a heavy chain variable region of the desired specificity was inserted just upstream.
f>.1.3. EXPRESSION OF PLATELET FACTOR 4/L6 FUSION PROTEIN
The construct was transfected into a murine myeloma cell line expressing the chimeric light chain and supernatants were screened for production of heavy/light assembled protein using anti-idiotypic antibodies specific for L6 V region determinants. Clones were established that tested positive for the presence of assembled heavy and light chain.
6.2. RESULTS AND DISCUSSION
The first example of an immunoglobulin fusion protein generated by this design incorporated the sequence of human platelet factor 4 downstrex~m as part of the L6 ~ chimeric heavy chain. Platelet factor 4 has been reported to have several biological activities of interest including heparin binding, antigonism of angiogenesis, inhibition of suppressor T lymphocyte development, chemotaxis for inflammatory cells, etc.
The growth and production characteristics (as determined by the Id/Id assay) for two clones are shown in Fig. 4. As can be seen by comparison with purified chimeric L6 as a standard, substantial amounts of Id bearing protein is produced, although it should be emphasized that chimeric L6 is a bivalent molecule that probably reacts somewhat differently than a chimeric F (ab) in this assay.
:l0 Culture supernatants from a clonal cell line were used to establish the PF4 nature of the heavy chain fusion protein. ELISA plates were coated with goat antisera specific for human platelet factor 4 (a kind gift from Dr. Karen Kaplan, Columbia Univeristy).
Supernatant from the producing clone was then added jointly in the presence of various concentrations of purified PF4 protein (Sigma), or media only. The plate was subsequently developed with the l5 biotinylated 13B anti-idiotype which recognizes an L6 combinatorial determinant, and avidin-HRP (TAGO). Fig. 5 shows a plot of the percent inhibition of the detectable signal with increasing amounts of the PF4 protein. No inhibition was observed by coincubation with chimeric L6 protein.
Since PF4 is normally capable of binding to heparin, that biological activity was :?0 characterized for the assembled fusion protein. Culture supernatant or media spiked with chimeric L6 protein was adsorbed on heparin-SEPHAROSE*. The amount of assembled protein was measured by an anti-Id assay requiring the presence of both light chain and combinatorial determinants (15B capture and 14B biotinylated to detect). The concentration before and after incubation with heparin-SEPHAROSE* is shown in Table 1, ?5 * Trade-mark Adsorption of L6PF4 and ChimFab to Heparin-Sepharose sup Conc (ng/ml)1) Heparin bound Before ads After ads (%) 6B3.7subc16 137 <5 <96 ChimFab 64 64 0 Expressed in ChimL6 eq. ( 15B - l4Bbio Elisa demonstrating that greater than 95% of the assembled Ig fusion protein is removable by heparin, a property not associated with the chimeric L6 molecule. The L6/PF4 fusion protein was also shown to bind to human tumor cells by FRCS
analysis using antisera specific for human Fab or human PF4.
These studies demonstrate that the basic design described here is useful for generating heavy chain fusion proteins that maintain dual characteristics and can be expressed at reasonable levels. t 7. EXAMPLE: CONSTRUCTION AND EXPRESSION
7.1. MATERIALS AND METHODS
7.1.1. CONSTRUCTION OF AN EXPRESSION VECTOR
FOR THE IL-2 ANTIBODY FUSION PROTEIN _.
A slightly different strategy was employed for the generation of L6/IL2 fusion protein, shown in Fig. 6.
These constructs began with the same pUCISC gammal 3'UT
shown in Fig. 2. This vector was opened with PstI and BamHI
~ to receive three DNA fragments. The first fragment was a pair of oligonucleotides encoding a modified version of the human hinge region in which the cysteines that normally mediate intermolecular linkage to another heavy chain have been replaced with codons specifying proline and serine ~ rt ,~ ~~ ~ .
', . . ) (shown as hinge in Fig. 7). The second section was formed by another pair of oligonucleotides (IL2 hinge gene linker sequence in Fig. 7) that has a 5' compatible overhang with that of the hinge pair, and a 3' overhang compatible with that of NcoI. This restriction site encompasses a colon sspecifying methionine and had been used for cloning the PF4 gene into bacterial expression vectors. The third component was the segment encoding the desired effector function (novel gene in Fig. 6) with an Ncol overhang at the 5' end and a BamHI overhang at the 3' end to complete ligation into 1~ the vector.
A separate construct was created by using oligonucleotides that encode each of the three cysteines normally present in the human IgGl hinge region, but with a stop colon immediately following the hinge sequence (Fig. 7 15 ( Fab' ) 2 ) .
Each assembled sequence was then transferred as a HindIII/Eco RI fragment to a vector containing a dominantly selectable gene (NEO) for transfection into eukaryotic cells. Subsequent to this step, either the cloned fragment ~~encoding the L6 heavy chain variable region, or the 2.3 kb HindIII fragment used for direct gene targeting to the IgH
locus, was cloned just upstream.
In the case of IL2, the coding region was generated using the polymerase chain reaction (PCR). The 25 overall procedure is outlined in Fig. 8. Peripheral blood cells from normal human donors were stimulated for s hours with anti-CD3 and anti-CD28 to elicit the production of IL2 RNA by the T cells within the population. Total cellular ~ RNA was then extracted from these cells and a single strand cDNA copy of the IL2 message was generated using primer IL2-3' as shown in Fig. 8. The portion of the IL2 coding region specified in Fig. 9 was amplified from this cDNA by the polymerase chain reaction using the primers IL2-5' and ~ IL2-3' (Fig. B). The 3' portion of each primer is perfectly homologous to the IL2 sequence, whereas the 5' region of each primer is mismatched to include an NcoI site at the 5' end and a BamHI site at the 3' end of the final product.
This PCR product was cloned as a blunt fragment into the SmaI site of pUCl9 for sequencing. Once the IL2 sequence 5was confirmed the coding region was transferred as an NcoI/BamHI fragment to the pUClBCgamma 13' UT plasmid as described above.
7.2. RESULTS AND DISCUSSION
7.2.1. EXPRESSION OF IL-2/L6 ANTIBODY FUSION PROTEIN
The L6/IL2 heavy chain fusion vector was cotransfected along with the chimeric light chain vector shown in Fig. 10 into either the Ag8.653 or Sp2/0 non-Ig l5producing murine plasmacytoma cell line. Selection was performed using 6418 and resistant cell populations were tested for production of bath heavy and light chain using a pair of anti-idiotypes, one specific for the L6 light chain variable region and the other specific for the heavy chain 20 variable region of L6. A single clone from the Ag8 transfection (103A4) was chosen for further study.
7.2.2. ASSAYS FOR BIFUNCTIONAL ACTIVITY
OF THE FUSION PROTEIN
Culture supernatant from this sell line Was used to demonstrate the dual functionality of the fusion protein in the following way. The human tumor cells (1x104) that bear the L6 antigen were irradiated and incubated with either media, 20~/ml of chimeric L6, 103A4 supernatant, ~ supernatant plus 20~/ml of murine L6 antibody, or supernatant plus 20p/ml of L6 anti-idiotype 14B. The cells were incubated for 30 minutes on ice, washed, and then mixed with 2x104 CTLL-2 cells which proliferate in response to IL2.
The proliferation was measurecl as a function of 3H-thymidine incorporation and the results were as follows:
TABLE I
3347s w/ CPM %INHIB
Media 8950 cL6 12151 103A4 Sup 78731 Sup + L6 11238 97 Sup + anti-id 13690 93 8. DEPOSIT OF MICROORGANISMS
The following microorganisms have been deposited with the Agricultural Research Culture Collection, Northern Regional Research Center (NRRL) and have been assigned the following accession numbers:
microorganism lasmid Accession No.
DHSa pPF-4/L6 NRRL B-18595 DHSa Pil-2/L6 NRRL B-18589 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
The present invention relates to a system for the generation of antibody fusion proteins which has utility in the production of recombinant molecules that possess novel, clinically relevant biological activity. The antibody fusion proteins of the invention may be used therapeutically to deliver biologically active ligands to a desired tissue.
In an embodiment of the invention there is provided an antibody-based fusion protein. The antibody-based fusion protein comprises a portion of an immunoglobulin molecule capable of directing the fusion protein to a tumor cell or a tumor associated antigen, and an interleukin-2 molecule capable of promoting lymphocyte proliferation.
In an embodiment of the invention there is provided the use of an antibody-based fusion protein comprising a portion of an immunoglobulin molecule capable of directing the fusion protein to a tumor cell or a tumor associated antigen and an interleukin-2 molecule capable of promoting lymphocyte proliferation to increase an anti-tumor response.
In an embodiment of the invention there is provided the use of an antibody-based fusion body protein comprising a portion of an immunoglobulin molecule capable of directing the fusion protein to a tumor cell or a tumor associated antigen, and an interleukin-2 molecule capable of promoting lymphocyte proliferation, in the preparation of a medicament useful to increase an -Sa-anti-tumor immune response.
In an embodiment of the invention there is provided use of an antibody-based fusion body protein comprising a portion of an immunogtobulin molecule capable of directing fusion protein to a tumor cell or a tumor associated antigen, and an interleukin-2 molecule capable of promoting lymphocyte proliferation in the preparation of a medicament useful to increase an anti-tumor immune response.
In particular embodiments of the invention, the antibody fusion protein comprises a biologically active ligand which is a lymphokine, including, in a specific embodiment, interleukin-2. Because interleukin-2 induces lymphocyte proliferation, fused antibody that targets interleukin-2 (IL-2) to a malignant or infected tissue can product localized amplification of the immune response toward the diseased tissue, and thereby facilitate the destruction of the infected or malignant tissue. In a specific embodiment of the invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active II-2.
Additional embodiments of the invention relate to fused antibodies which comprise an immunoglobulin variable region and a biologically active ligand which is a non-lymphokine cellular factor. In a specific embodiment of the »; , e: i ~') ~a 1, - "~
invention, a fused antibody is produced which comprises a variable region of the anti-tumor antigen monoclonal antibody L6 and active platelet factor 4, a molecule associated with antagonism of angiogenesis, .inhibition of suppressor T lymphocyte development, chemotaxis and heparin x>inding.
DESCRIPTION OF THE FIGURES
Figure 1. Diagram of insertion of CH1 into pUCl8 vector.
Figure 2. Diagram of insertion of PF-4 cDNA into CHl, Hinge-Bearing Vector.
Figure 3. Diagram of insertion of construct into a mammalian expression vector.
Figure 4. Production of PF-4/L6 fusion protein by cell lines transfected with PF-4/L6 expression vector, as measured by reactivity with anti-L6 idiotype antibody.
Figure 5. Inhibition of binding of anti-PF-4 antibody to PF-~/L6 fusion protein by increasing concentrations of free PF-4.
Figure 6. Diagram of strategy for the generation of IL-2/L6 20 fusion proteins. (a) insertion of IL-2 cDNA into pUCl8 vector containing CH1 amd 3' untranslated regions (3'uT) from the mouse immunoglobulin gene locus with incorporation of hinge/linker sequences; (b) final expression vector comprising SV40ori promoter and the 25 neo resistance gene.
Figure 7. Exact hinge (a) and hinge-linker (b) sequences.
Figure 8. Procedure of producing IL-2 cDNA for cloning.
Figure 9. Coding portion of IL-2 amplified in polymerase chain reaction.
~ Figure 10. Chimeric light chain vector cotransfected with pIL-2/L6 .
s'~ ; a r~ .? .~
Y.,I '. ~~
5. DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a system for the generation of therapeutic antibody fusion proteins. In particular, the present invention relates to therapeutic antibody fusion proteins as well as the recombinant DNA
5molecules utilized in their production. For purposes of clarity of disclosure, and not by way of limitation, the detailed description of the invention will be divided into the following subsections:
(i) construction of recombinant genes encoding antibody fusion proteins;
(ii) expression of antibody fusion proteins; and (iii) utility of the invention.
5.1. CONSTRUCTION OF RECOMBINANT GENES
The antibody-based fusion proteins of the invention comprise (i) a portion of an immunoglobulin ...:,lecule capable of directing the fusion protein to an intended cell or tissue and (ii) a biologically active 20protein or peptide. The recombinant genes encoding the antibody fusion proteins of the invention may be constructed using any technique known in the art of molecular biology, including but not limited to the following.
The targeting portion of the molecule may 25comprise all ar part of an immunoglobulin variable region which.may, in turn, be comprised of regions encoded by a V
gene and/or D gene and/or J gene. In preferred embodiments of the inventian, the antibody fusion proteins comprise a portion corresponding to the hinge region of an ~immunoglobulin molecule, or a functional equivalent thereof which would provide flexibility between the globular domains of the antibody-based fusion protein. A functional hinge may be important in retaining targeting ability. Variable regions of antibody, particularly monoclonal antibody, that ~
',; ; : ; j r'.f ? 1 (.~ '' .. ..
-g-recognize tumor-specific antigens, viral-specific antigens, bacterial antigens, parasite antigens, or antigens expressed on a particular population of cells (such as lymphocytes) may be used in fusion proteins of the invention.
Ligands which may be incorporated into the antibody-based fusion proteins of the invention include but are not limited to lymphokines and cellular factors which interact with specific cellular receptor. Lymphokines of the invention include but are not limited to interleukin-1 (Henderson and Pettipher, 1988, Biochem. Pharmacol.
~B 37:4717); interleukin-2 (Weil-Hillman et al., 1988, J. Biol.
Response Mod. 7:424); interleukin-6 (Van Damme et al., 1987, J. Exp. Med. 165:914-919); interferon a (Piths et al., 19898, J. Immunol. 141:3611): and interferon y (Blanchard and Djeu, 1988, J. Immunol. 141:4067).
Cellular factors which may be incorporated into the antibody-based fusion proteins of the invention include but are not limited to platelet factor 4 (bevel et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:4584-4587): tumor necrosis factor a (Plate et al, 1988, Ann. N.Y. Acad. Sci.
2Q 532:149); epidermal growth factor (carpenter arid Cohen, A.
Rev. Biochem. 48:193-216): fibroblast growth factor (Folkman and Klagsburn, 1987, Science 235:442-447): insulin-like growth factor-1 (Blundell and Humbel, 1980, Nature 287:781-787); insulin-like growth factor-2 (Blundell and Humbel, 25 supra) platelet-derived growth factor (Ross et al., 1986, Cell 46:155-169); transforming growth factor a (Derynck, 1988, Cell 54:593-595)p transforming growth factor ~
(Cheifetz et al., 1987, Cell 48:409-416): interferon ~ and nerve growth factor (Thoenen et al., 1982, in "Repair and ~ Regeneration of the Nervous System", J.G. Nicholls, ed., Springer-Verlag, NY, pp. 173-185).
Recombinant nucleic acid molecules which encode the immunoglobulin, lymphokine or growth factor may be ~ obtained by any method known in the art (Maniatis et al., r't ~..~ ~~ ~ 'i ~1 _g_ 1982, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) or obtained from publicly available clones. For example, nucleic acid encoding a lymphokine or factor may be obtained as follows.
A population of cells known to actively express the factor smay be obtained, and total cellular RNA may be harvested therefrom. Amino acid sequence of the factor may be used to deduce the sequence of a portion of the factor's nucleic acid so as to design appropriate oligonucleotide primers, or, alternatively, the oligonucleotide primers may be t0obtained from a known nucleic acid sequence which encodes the factor. The oligonucleotide fragment may then be used in conjunction with reverse transcriptase to produce cDNA
corresponding to factor-encoding nucleotide sequence (Okayama et al., 1987, Methods Enzymol. 154:3-29). The cDNA
~5can then be cloned, and/or portions of the factor coding region may then be amplified from this cDNA using polymerase chain reaction and appropriate primer sequences, (Saiki et al., 1988, Science 239:487-491).
In particular embodiments of the invention, a ZOrecombinant vector system may be created to accommodate sequences encoding the ligand in the correct reading frame with a natural or synthetic hinge region. For example, and not by way of limitation, the hinge region of the human IgGl constant region may be used: in a specific embodiment of the ZSinvention, the constant region axon encoding the CHl domain of human IgGl may be cloned as a HindIII-PstI fragment into the vector pUClB to which may be joined, using standard restriction enzyme techniques, a modified version of the human hinge region sequences of human IgGl. In the modified version of the human hinge region, the two cysteine residues that normally mediate interchain disulfide linkage may be replaced by codons specifying proline and serine so as to permit greater flexibility in the fused molecule: in this ~~ t3 ~i ,i ;
_1~_ s.e ' specific embodiment the sequence of the hinge region may be EF~KS CDKTHTPPPS PGRWGGRA .
Additionally, it may be desirable to include, as part of the recombinant vector system, nucleic acids corresponding to the 3' flanking region of an immunoglobulin 5ge:ne including RNA cleavage/polyadenylation sites and downstream sequences; according to a specific embodiment of the invention, this nucleotide sequence provides the mRNA
with the 3' untranslated region of the secretory form of the murine C~ gene. Furthermore, it may be desirable to ~~engineer a signal sequence upstream of the antibody fusion protein-encoding sequences to facilitate the secretion of the fused molecule from a cell transformed with the recombinant vector.
Nucleic acid sequences encoding the various i5components of the antibody-based fusion proteins of the invention may be joined together using any techniques known in the art, including restriction enzyme methodologies and the use of synthetic linker sequences.
To provide for adequate transcription of the 2precombinant constructs of the invention, a suitable promoter/enhancer sequence may preferably be incorporated into the recombinant vector. Promoters which may be used to control the expression of the antibody-based fusion protein include, but are not limited to, the SV40 early promoter 25region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3° long terminal repeat of Rous sarcoma virus (Yamamota, st al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc.
~Natl. Acad. Sci. U.S.A. 78:144-1445), the regulatory sequences of the metallothionine gene (Brinster et al., 1982, Nature 296:39-42): prokaryotic expression systems such as the LAC, or ~-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac ~a phage promoter (DeBoer, et al., 1983, Proc. Natl. Acad.
Sci. U.S.A. 80:21-25), see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; plant expression vectors comprising the nopaline s;~nthetase promoter region (Herrera-Estrella et al., Nature _30_3:209-213) or the cauliflower mosaic virus 35S RNA promoter s(Gardner, et al., 1981, Nucl. Acids Res. 9:2871), and the promoter for the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310:115°
120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK
~D(phosphoglycerol kinase) promoter, alkaline phophatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et ~5a1., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515)p insulin gene enhancers or promoters which are active in pancreatic beta sells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene enhancers or 20promoters which are active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658: Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol.
7:1436-1444), the cytomegalovirus early promoter and enhancer regions (Boshart et al., 1985, Cell _41:521-530), mouse 2Smammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel.
X1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol.
5:1639-1648: Hammer et al., 1987, Science 235:53-58): alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al, 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid / . a J :1 F,.,~ .5 '( cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712): myosin light chain-2 gene control region which is active in skeletal 5muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).
Successful incorporation of antibody-based fusion gene constructs may be identified by three general 1~ approaches: (a) DNA-DNA hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising sequences ~5 that are homologous to the inserted antibody fusion protein gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e. g., thymidine kinase activity, resistance to antibiotics such as 20 6418, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the antibody fusion gene is inserted so as to interrupt the marker gene sequence of the vector, recombinants containing the antibody fusion gene 25 insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be ~ based, for example, on the physical or functional properties of the antibody fusion gene product in bioassay systems as described infra.
Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may ~ be used to propagate it. Once a suitable host system and -1.3- '3 ;: ;i ''~ '~
y ,. ,:, . . . : : ...
growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be ua;ed include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as 5vaccinia virus, adenovirus or retroviral based vectors;
insect viruses such as baculovirus; yeast vectors:
bacteriophage vectors (e. g., lambda), and plasmid and cosmid DNA vectors, to name but a few.
In a preferred embodiment of the invention, the ~~promoter/enhancer and 3' regulatory sequences may all be derived from immunoglobulin genes.
5.2. EXPRESSION OF ANTIBODY FUSION PROTEINS
The recombinant constructs of the invention may ~5be introduced into host cells which are capable of expressing the antibody-based fusion protein using any method known in the art, including transformation (for example, using DEAF-dextran or calcium phosphate techniques), transfection, microinjection, infection, cell 20gun, and electroporation. Any host cell type may be utilized provided that the antibody-based fusion protein recombinant nucleic acid sequences would be adequately transcribed into mRNA in that cell type. In specific embodiments of the invention, mouse myeloma cell lines which ?5~o not produce immunoglobulin, such as Sp2/o or Ag8.653 may b~~ used. In addition, the recombinant nucleic acid constructs of the invention may be used to create non-human transgenic animals capable of producing the antibody based fusion protein. 3n preferred embodiments of the invention, the host cell is a lymphoid call. In specific embodiments of the invention, the host cell is a hybridoma derived heavy chain loss variant which expresses immunoglobulin light chains: in this embodiment, the parent hybridoma most preferably may be the source of the monoclonal antibody which comprises the immunoglobulin portions of the antibody-based fusion protein. Thus, for example, and not by way of limitation, the light-chain producing cell line derived from a hybridoma which produces monoclonal antibody "X" may be transfected with recombinant DNA encoding an antibody-based fusion protein which comprises a variable region of monoclonal antibody "X" ; the antibody-based fusion protein may combine with endogenous light chain and thereby re-create the antigen binding site of monoclonal antibody "X" .
Alternatively, recombinant nucleic acids encoding both antibody-based fusion protein and corresponding or compatible immunoglobulin light chain may be cotransfected into a cell line which is preferably of lymphoid origin. In yet a further embodiment of the invention, the antibody fusion protein encoding sequences may be introduced into the immunoglobulin locus of a lymphoid cell line by homologous recombination.
Antibody-based fusion protein produced by the host cell may be collected using any technique known in the art, including, but not limited to, affinity chromatography using target antigen or antibody specific for any portion of the fusion protein including, for example, anti-idiotype antibody. The activity of the fused lymphokine or cellular factor may be confirmed using biological assays which detect or measure the activity of the lymphokine or cellular factor. For example, and not by way of limitation, if IL-2 is the lymphokine comprised by the antibody fusion protein, the presence of IL-2 activity may be confirmed in assays which detect T-cell proliferation. In a specific embodiment of the invention, the presence of PF4 activity is confirmed by observing that the antibody fusion protein binds to anti-PF4 antibody in a manner which is competitively inhibited by free, unconjugated PF4 protein.
The present invention provides for dimeric immunoglobulin molecules as well as monomeric or multimeric molecules comprising antibody based fusion proteins.
5.3. UTILITY OF THE INVENTION
The present invention provides for antibody based fusion proteins that may be used to deliver biologically active ligand molecules to specific target cells or tissues. In particular embodiments of the invention, the antibody fusion proteins comprise ligands which are lymphokines or other cellular factors.
In various embodiments of the invention, an antibody fusion protein may comprise variable region sE:quences which recognize a tumor specific antigen.
According to a specific embodiment of the invention, the variable region sequences are derived from L6, a monoclonal antibody which reacts with an antigen present on human non-small cell lung carcinoma and a number of other carcinomas, including breast and colon carciinoma (ATCC Accession Number HB 8677). If the antibody fusion molecule which recognizes a tumor specific antigen also comprises a lymphokine, it may be used to alter the immune response in the area of the tumor cells. For example, as shown in Example Section 7, infra, an antibody fusion protein comprising IL-2 and the IL6 variable region retains IL-2 activity. The fusion protein may be used to target IL-2 to tumor cells; consequently, activated T-cells in the vicinity of the tumor will be induced to proliferate, thereby amplifying the anti-tumor immune response. It should be noted that current immunotherapy often involves systemic administration of lymphokines at a concentration that is intended to effectively boost anti-tumor activity but which necessarily affects lymphocytes and tissues throughout the body. In the case of IL-2, severe -16- ~ f' and potentially fatal clinical reactions may occur. The present invention offers the advantage of decreasing systemic exposure to lymphokine; antibody-mediated targeting allows for less total lymphokine to be administered and 5substantially decreases the exposure of non-tumor tissues to lymphokine, thereby minimizing toxic effects. In a further specific embodiment, a PF4/L6 antibody may be used to inhibit angiogenesis at a tumor site and thereby inhibit tumor growth.
In additional embodiments, the antibady fusion 'oproteins of the invention may be directed toward antigens associated with infectious agents, including viral, bacterial, or parasitic antigens. In a specific embodiment, the antibody fusion protein may comprise a chemotactic factor which may be used to recruit polymorphonuclear ~5leukocytes to sites of infection, including the walls of abscesses.
Alternatively, the antibody fusion proteins of the invention may be directed toward antigens present on a subpopulation of cells in the body. For example, antibody 2~fusion proteins directed toward antigens on the surface of helper T-cel~.s could be used to target ligands which augment helper cell activity in immune compromised patients or to target ligands that down regulate T-helper responses in cases of autoimmunity. Alternatively, antibody fusion 25proteins directed toward antigens on the surface of suppressor T-cells may be used to regulate activity.
Subpopulations of cells could also be targeted based on receptor specificity (e. g. antigen for lymphocytes).
In additional embodiments of the invention, cellular factors that relate to wound healing may be incorporated into antibody fusion proteins. For example, fibroblast growth factor may be combined with an antibody ' which recognizes an antigen exposed by or applied to an area ~ of cell injury.
~~°~1.'?;5.
--17_ , The antibody fusion proteins may be administered to a patient in need of such treatment in any sterile pharmaceutical carrier which will maintain the solubility and activity of the protein. It may be desirable to administer antibody fusion proteins in conjunction with Bother treatment modalities, including antibodies and/or antibody fusion proteins comprising additional growth factors.
6. EXAMPLE: CONSTRUCTION AND EXPRESSION OF
6.1. MATERIALS AND METHODS
6.1.1. CONSTRUCTION OF AN EXPRESSION CASSETTE
FOR AN ANTIBODY-BASED FUSION PROTEIN
A recombinant vector system was created to 'Saccommodate sequences encoding novel protein structure in the correct reading frame with the hinge region of the human IgGl constant region. Initially,'the constant region axon encoding the CHl domain of human IgG1 was cloned as a HindIII/PstI fragment into the vector pUCl8 (Fig. 1).
Z~Downstream of these sequences was cloned a 1.6 kb Pstl/KpnI
fragment containing a portion of the 3' flanking region of the murine C~ gene that includes the RNA cleavage/
polyadenylation sites used in the expression of mRNA
encoding the secretory form of IgM heavy chain. A portion c ~~'of the vector polylinker was retained between the two fragments for subsequent additions.
A pair of oligonucleotides was generated that when annealed encode a modified version of the human hinge ~ region sequences of human IgGl: The two cysteines that normally mediate interchain disulfide linkage between heavy chains were replaced with codons specifying proline and serine, and several amino acids were added to the carboxy terminus such that the entire hinge region sequence is:
~EPKSCDKTHTPPPSPGRWGGRA. The annealed oligonucleotide pair i ~ J~~ F/ cj ~_ has a PstI compatible overhang on the 5' end, includes the rnormal splice acceptor site for the hinge axon, and retains another suitable overhang for linkage with additional oligonucleotides at the 3' end. A second pair of oligonucleotides was designed to overlap with the first set s and provide compatible ends for ligation with an NcoI
overhang.
6.1.2. INSERTION OF PLATELET FACTOR 4 ENCODTNG
SEQUENCES INTO ANTIBODY FUSION PROTEIN
CASSETTE
The cDNA clone encoding human platelet factor 4 (PF4) was linked as an NcoI/Baml fragment in frame with the hinge region by ligation into the PstI/BamI sites of the vector with the two pairs of oligonucleotides at the 5' end ~5(Fig. 2). The fusion construct was then transferred to a vector that contains a dominant selectable marker (NEO) for expression in mammalian cells (Fig. 3), and then a gene segment encoding a heavy chain variable region of the desired specificity was inserted just upstream.
f>.1.3. EXPRESSION OF PLATELET FACTOR 4/L6 FUSION PROTEIN
The construct was transfected into a murine myeloma cell line expressing the chimeric light chain and supernatants were screened for production of heavy/light assembled protein using anti-idiotypic antibodies specific for L6 V region determinants. Clones were established that tested positive for the presence of assembled heavy and light chain.
6.2. RESULTS AND DISCUSSION
The first example of an immunoglobulin fusion protein generated by this design incorporated the sequence of human platelet factor 4 downstrex~m as part of the L6 ~ chimeric heavy chain. Platelet factor 4 has been reported to have several biological activities of interest including heparin binding, antigonism of angiogenesis, inhibition of suppressor T lymphocyte development, chemotaxis for inflammatory cells, etc.
The growth and production characteristics (as determined by the Id/Id assay) for two clones are shown in Fig. 4. As can be seen by comparison with purified chimeric L6 as a standard, substantial amounts of Id bearing protein is produced, although it should be emphasized that chimeric L6 is a bivalent molecule that probably reacts somewhat differently than a chimeric F (ab) in this assay.
:l0 Culture supernatants from a clonal cell line were used to establish the PF4 nature of the heavy chain fusion protein. ELISA plates were coated with goat antisera specific for human platelet factor 4 (a kind gift from Dr. Karen Kaplan, Columbia Univeristy).
Supernatant from the producing clone was then added jointly in the presence of various concentrations of purified PF4 protein (Sigma), or media only. The plate was subsequently developed with the l5 biotinylated 13B anti-idiotype which recognizes an L6 combinatorial determinant, and avidin-HRP (TAGO). Fig. 5 shows a plot of the percent inhibition of the detectable signal with increasing amounts of the PF4 protein. No inhibition was observed by coincubation with chimeric L6 protein.
Since PF4 is normally capable of binding to heparin, that biological activity was :?0 characterized for the assembled fusion protein. Culture supernatant or media spiked with chimeric L6 protein was adsorbed on heparin-SEPHAROSE*. The amount of assembled protein was measured by an anti-Id assay requiring the presence of both light chain and combinatorial determinants (15B capture and 14B biotinylated to detect). The concentration before and after incubation with heparin-SEPHAROSE* is shown in Table 1, ?5 * Trade-mark Adsorption of L6PF4 and ChimFab to Heparin-Sepharose sup Conc (ng/ml)1) Heparin bound Before ads After ads (%) 6B3.7subc16 137 <5 <96 ChimFab 64 64 0 Expressed in ChimL6 eq. ( 15B - l4Bbio Elisa demonstrating that greater than 95% of the assembled Ig fusion protein is removable by heparin, a property not associated with the chimeric L6 molecule. The L6/PF4 fusion protein was also shown to bind to human tumor cells by FRCS
analysis using antisera specific for human Fab or human PF4.
These studies demonstrate that the basic design described here is useful for generating heavy chain fusion proteins that maintain dual characteristics and can be expressed at reasonable levels. t 7. EXAMPLE: CONSTRUCTION AND EXPRESSION
7.1. MATERIALS AND METHODS
7.1.1. CONSTRUCTION OF AN EXPRESSION VECTOR
FOR THE IL-2 ANTIBODY FUSION PROTEIN _.
A slightly different strategy was employed for the generation of L6/IL2 fusion protein, shown in Fig. 6.
These constructs began with the same pUCISC gammal 3'UT
shown in Fig. 2. This vector was opened with PstI and BamHI
~ to receive three DNA fragments. The first fragment was a pair of oligonucleotides encoding a modified version of the human hinge region in which the cysteines that normally mediate intermolecular linkage to another heavy chain have been replaced with codons specifying proline and serine ~ rt ,~ ~~ ~ .
', . . ) (shown as hinge in Fig. 7). The second section was formed by another pair of oligonucleotides (IL2 hinge gene linker sequence in Fig. 7) that has a 5' compatible overhang with that of the hinge pair, and a 3' overhang compatible with that of NcoI. This restriction site encompasses a colon sspecifying methionine and had been used for cloning the PF4 gene into bacterial expression vectors. The third component was the segment encoding the desired effector function (novel gene in Fig. 6) with an Ncol overhang at the 5' end and a BamHI overhang at the 3' end to complete ligation into 1~ the vector.
A separate construct was created by using oligonucleotides that encode each of the three cysteines normally present in the human IgGl hinge region, but with a stop colon immediately following the hinge sequence (Fig. 7 15 ( Fab' ) 2 ) .
Each assembled sequence was then transferred as a HindIII/Eco RI fragment to a vector containing a dominantly selectable gene (NEO) for transfection into eukaryotic cells. Subsequent to this step, either the cloned fragment ~~encoding the L6 heavy chain variable region, or the 2.3 kb HindIII fragment used for direct gene targeting to the IgH
locus, was cloned just upstream.
In the case of IL2, the coding region was generated using the polymerase chain reaction (PCR). The 25 overall procedure is outlined in Fig. 8. Peripheral blood cells from normal human donors were stimulated for s hours with anti-CD3 and anti-CD28 to elicit the production of IL2 RNA by the T cells within the population. Total cellular ~ RNA was then extracted from these cells and a single strand cDNA copy of the IL2 message was generated using primer IL2-3' as shown in Fig. 8. The portion of the IL2 coding region specified in Fig. 9 was amplified from this cDNA by the polymerase chain reaction using the primers IL2-5' and ~ IL2-3' (Fig. B). The 3' portion of each primer is perfectly homologous to the IL2 sequence, whereas the 5' region of each primer is mismatched to include an NcoI site at the 5' end and a BamHI site at the 3' end of the final product.
This PCR product was cloned as a blunt fragment into the SmaI site of pUCl9 for sequencing. Once the IL2 sequence 5was confirmed the coding region was transferred as an NcoI/BamHI fragment to the pUClBCgamma 13' UT plasmid as described above.
7.2. RESULTS AND DISCUSSION
7.2.1. EXPRESSION OF IL-2/L6 ANTIBODY FUSION PROTEIN
The L6/IL2 heavy chain fusion vector was cotransfected along with the chimeric light chain vector shown in Fig. 10 into either the Ag8.653 or Sp2/0 non-Ig l5producing murine plasmacytoma cell line. Selection was performed using 6418 and resistant cell populations were tested for production of bath heavy and light chain using a pair of anti-idiotypes, one specific for the L6 light chain variable region and the other specific for the heavy chain 20 variable region of L6. A single clone from the Ag8 transfection (103A4) was chosen for further study.
7.2.2. ASSAYS FOR BIFUNCTIONAL ACTIVITY
OF THE FUSION PROTEIN
Culture supernatant from this sell line Was used to demonstrate the dual functionality of the fusion protein in the following way. The human tumor cells (1x104) that bear the L6 antigen were irradiated and incubated with either media, 20~/ml of chimeric L6, 103A4 supernatant, ~ supernatant plus 20~/ml of murine L6 antibody, or supernatant plus 20p/ml of L6 anti-idiotype 14B. The cells were incubated for 30 minutes on ice, washed, and then mixed with 2x104 CTLL-2 cells which proliferate in response to IL2.
The proliferation was measurecl as a function of 3H-thymidine incorporation and the results were as follows:
TABLE I
3347s w/ CPM %INHIB
Media 8950 cL6 12151 103A4 Sup 78731 Sup + L6 11238 97 Sup + anti-id 13690 93 8. DEPOSIT OF MICROORGANISMS
The following microorganisms have been deposited with the Agricultural Research Culture Collection, Northern Regional Research Center (NRRL) and have been assigned the following accession numbers:
microorganism lasmid Accession No.
DHSa pPF-4/L6 NRRL B-18595 DHSa Pil-2/L6 NRRL B-18589 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Claims (5)
1. An antibody-based fusion protein comprising:
(i) a portion of an immunoglobulin molecule capable of directing the fusion protein to a tumor cell or a tumor associated antigen, and (ii) an interleukin-2 molecule capable of promoting lymphocyte proliferation.
(i) a portion of an immunoglobulin molecule capable of directing the fusion protein to a tumor cell or a tumor associated antigen, and (ii) an interleukin-2 molecule capable of promoting lymphocyte proliferation.
2. The antibody-based fusion protein of claim 1 in which the portion of the immunoglobulin molecule competitively inhibits the binding of monoclonal antibody L6, produced by hybridoma L6 and deposited with the ATCC having accession number HB 10269.
3. Use of the antibody-based fusion protein of claim 1 to increase an anti-tumor immune response.
4. The use of claim 3 in which the portion of the immunoglobulin molecule is capable of competitively inhibiting the binding of L6 antibody, produced by hyridoma deposited with the ATCC and having accession number HB10269.
5. Use of the antibody-based fusion protein of claim 1 in the preparation of a medicament useful to increase an anti-tumor immune response.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US468,390 | 1990-01-22 | ||
| US07/468,390 US5314995A (en) | 1990-01-22 | 1990-01-22 | Therapeutic interleukin-2-antibody based fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2034741A1 CA2034741A1 (en) | 1991-07-23 |
| CA2034741C true CA2034741C (en) | 2002-03-12 |
Family
ID=23859613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002034741A Expired - Lifetime CA2034741C (en) | 1990-01-22 | 1991-01-22 | Therapeutic antibody based fusion proteins |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5314995A (en) |
| EP (2) | EP0439095B2 (en) |
| JP (1) | JP3171268B2 (en) |
| AT (2) | ATE227776T1 (en) |
| CA (1) | CA2034741C (en) |
| DE (2) | DE69129421T3 (en) |
| DK (2) | DK0439095T4 (en) |
| ES (2) | ES2115596T5 (en) |
| GR (1) | GR3027613T3 (en) |
Families Citing this family (326)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| EP0521985B1 (en) * | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| US6458360B1 (en) * | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| DK0574395T3 (en) * | 1990-11-09 | 2002-10-07 | Stephen D Gillies | Cytokine immunoconjugates |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| GB9121815D0 (en) * | 1991-10-15 | 1991-11-27 | Delta Biotechnology Ltd | Medicine |
| FR2698880B1 (en) * | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Process for the production of soluble T receptors, products thus obtained and their use in diagnostic or therapeutic compositions. |
| WO1995012414A1 (en) * | 1993-11-05 | 1995-05-11 | Repligen Corporation | Novel modified pf4 compositions and methods of use |
| DK0659439T3 (en) * | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | immunoconjugates |
| US5667987A (en) * | 1994-07-12 | 1997-09-16 | Bristol-Myers Squibb Company | P53 response genes |
| IT1271688B (en) * | 1994-08-04 | 1997-06-04 | Menarini Ricerche Sud Spa | HYBRID MOLECULES FOR ANTI-CANCER TREATMENT THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS |
| FR2724320B1 (en) * | 1994-09-13 | 1996-12-20 | Transgene Sa | NEW IMPLANT FOR THE TREATMENT OF ACQUIRED DISEASES |
| EP0706799B1 (en) * | 1994-09-16 | 2001-11-14 | MERCK PATENT GmbH | Immunoconjugates II |
| US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| AU1952497A (en) * | 1996-02-13 | 1997-09-02 | Regents Of The University Of California, The | Novel antibody-cytokine fusion protein, and methods of making and using the same |
| US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
| US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| US6852508B1 (en) | 1997-02-28 | 2005-02-08 | Genetics Institute, Llc | Chemokine with amino-terminal modifications |
| GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US7569674B2 (en) * | 1998-05-04 | 2009-08-04 | Innexus Biotechnology International Limited | Autophilic antibodies |
| US20040185039A1 (en) * | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
| US20030103984A1 (en) * | 1998-05-04 | 2003-06-05 | Heinz Kohler | Fusion proteins of biologically active peptides and antibodies |
| US20050033033A1 (en) * | 1998-05-04 | 2005-02-10 | Heinz Kohler | Trans-membrane-antibody induced inhibition of apoptosis |
| ATE243045T1 (en) * | 1997-11-20 | 2003-07-15 | Vical Inc | TREATMENT OF CANCER BY USING CYTOKINE-EXPRESSING POLYNUCLEOTIDES AND COMPOSITIONS THEREOF |
| EP1037927B1 (en) | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| AU3072799A (en) | 1998-03-19 | 1999-10-11 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
| JP2002511432A (en) * | 1998-04-15 | 2002-04-16 | レキシジェン ファーマシューティカルズ コーポレイション | Enhancement of antibody-cytokine fusion protein-mediated immune response by co-administration of an angiogenesis inhibitor |
| US20090208418A1 (en) * | 2005-04-29 | 2009-08-20 | Innexus Biotechnology Internaltional Ltd. | Superantibody synthesis and use in detection, prevention and treatment of disease |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| PL200919B1 (en) * | 1999-02-12 | 2009-02-27 | Lexigen Pharm Corp | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| US6869606B1 (en) | 1999-02-22 | 2005-03-22 | Millennium Pharmaceuticals, Inc. | Biotinylated-chemokine antibody complexes |
| EP1161451A4 (en) | 1999-02-26 | 2006-05-17 | Human Genome Sciences Inc | Human endokine alpha and methods of use |
| PT1187852E (en) * | 1999-05-19 | 2007-11-14 | Merck Patent Gmbh | Expression and export of interferon-alpha proteins as fc fusion proteins |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| MXPA02001417A (en) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Multiple cytokine-antibody complexes. |
| US7569542B2 (en) | 1999-08-20 | 2009-08-04 | The Regents Of The University Of California | Anti-microbial targeting chimeric pharmaceutical |
| US20030143234A1 (en) * | 1999-08-20 | 2003-07-31 | Wenyuan Shi | Anti-microbial targeting chimeric pharmaceutical |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| WO2001036489A2 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gmbh | Erythropoietin forms with improved properties |
| AU4314801A (en) * | 2000-02-11 | 2001-08-20 | Lexigen Pharm Corp | Enhancing the circulating half-life of antibody-based fusion proteins |
| CA2404088A1 (en) * | 2000-03-23 | 2001-09-27 | Greenville Hospital System | Bi-functional cancer treatment agents |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| CA2413160A1 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| CA2407910C (en) | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
| EP1292334A4 (en) * | 2000-06-22 | 2003-11-19 | Idec Pharma Corp | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| CN1270775C (en) * | 2000-06-29 | 2006-08-23 | 默克专利有限公司 | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enbancing agents |
| EP1674477B1 (en) | 2000-08-18 | 2009-12-09 | Dyax Corp. | Binding polypeptides for B lymphocyte stimulator protein (BLYS) |
| WO2002016411A2 (en) | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
| EP2412384A1 (en) | 2000-11-28 | 2012-02-01 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| GB0029407D0 (en) * | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| ES2727425T3 (en) | 2000-12-12 | 2019-10-16 | Medimmune Llc | Molecules with prolonged half-lives, compositions and uses thereof |
| US7445802B2 (en) * | 2000-12-26 | 2008-11-04 | Yeda Research And Development Co. Ltd | Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1683865A3 (en) | 2001-02-02 | 2006-10-25 | Eli Lilly & Company | Mammalian proteins and in particular CD200 |
| CN1564826A (en) | 2001-02-09 | 2005-01-12 | 人类基因组科学公司 | Human G-protein chemokine receptor (CCR5) HDGNR10 |
| KR100900176B1 (en) * | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | Expression technology for proteins containing a hybrid isotype antibody moiety |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| JP2004536579A (en) | 2001-04-13 | 2004-12-09 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | Vascular endothelial growth factor 2 |
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| DK1383785T3 (en) * | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Recombinant tumor-specific antibody and its use |
| US7064189B2 (en) | 2001-05-25 | 2006-06-20 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US20020193569A1 (en) * | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| CA2349506C (en) | 2001-06-14 | 2009-12-08 | Duke University | A method for selective expression of therapeutic genes by hyperthermia |
| US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
| AU2002357784B2 (en) | 2001-12-04 | 2008-07-31 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
| WO2003062395A2 (en) * | 2002-01-18 | 2003-07-31 | Bristol-Myers Squibb Company | Predictor sets for tyrosine kinase pathways |
| US20030216315A1 (en) | 2002-02-13 | 2003-11-20 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
| US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
| CA2479306A1 (en) * | 2002-03-19 | 2003-10-02 | The Penn State Research Foundation | Egfr ligands and methods of use |
| EP1497445A2 (en) * | 2002-04-01 | 2005-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| EP1499352A4 (en) | 2002-04-12 | 2006-10-11 | Medimmune Inc | Recombinant anti-interleukin-9 antibodies |
| AU2003248545B2 (en) * | 2002-05-16 | 2006-08-24 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins |
| US7563882B2 (en) * | 2002-06-10 | 2009-07-21 | University Of Rochester | Polynucleotides encoding antibodies that bind to the C35 polypeptide |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
| WO2004035537A2 (en) | 2002-10-16 | 2004-04-29 | Euro-Celtique S.A. | Antibodies that bind cell-associated ca 125/o772p and methods of use thereof |
| PT1572748E (en) * | 2002-12-17 | 2010-09-28 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| JP2006518997A (en) * | 2003-01-21 | 2006-08-24 | ブリストル−マイヤーズ スクイブ カンパニー | Novel acyl coenzyme A: polynucleotide encoding monoacylglycerol acyltransferase-3 (MGAT3) and uses thereof |
| ES2537015T3 (en) * | 2003-03-19 | 2015-06-01 | Biogen Ma Inc. | NOGO receptor binding protein |
| EP2266628A3 (en) | 2003-05-13 | 2012-01-18 | Novartis Vaccines and Diagnostics, Inc. | Method of determining the susceptibility to bone meatastases by EPhA2 expression |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| EP2272566A3 (en) | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisation of antibodies |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| WO2005037999A2 (en) * | 2003-10-14 | 2005-04-28 | Biogen Idec Ma Inc. | Treatment of cancer using antibodies to lrrc15 |
| EP1708751B1 (en) * | 2003-12-04 | 2011-09-28 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| SG10201404273QA (en) | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| BRPI0418286A (en) | 2003-12-30 | 2007-05-02 | Merck Patent Gmbh | il-7 fusion proteins |
| CA2551916C (en) * | 2003-12-31 | 2014-04-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| CA2553883C (en) | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| US20060019914A1 (en) | 2004-02-11 | 2006-01-26 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes |
| US7875598B2 (en) * | 2004-03-04 | 2011-01-25 | The Regents Of The University Of California | Compositions useful for the treatment of microbial infections |
| US7973139B2 (en) | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| EP2138195A3 (en) | 2004-06-16 | 2010-07-21 | Affinergy Inc. | IFBM's to promote attachment of target analytes |
| US8486893B2 (en) | 2004-06-24 | 2013-07-16 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| WO2006017673A2 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
| WO2006034292A2 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| US20060121042A1 (en) | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| EP1819728B1 (en) * | 2004-12-09 | 2010-04-21 | MERCK PATENT GmbH | Il-7 variants with reduced immunogenicity |
| WO2006078776A2 (en) * | 2005-01-19 | 2006-07-27 | The Trustees Of The University Of Pennsylvania | Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors |
| JP5153613B2 (en) | 2005-03-18 | 2013-02-27 | メディミューン，エルエルシー | Antibody framework shuffle |
| EP1891111A1 (en) | 2005-05-06 | 2008-02-27 | ZymoGenetics, Inc. | Il-31 monoclonal antibodies and methods of use |
| WO2007002543A2 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| EP1904652A2 (en) * | 2005-07-08 | 2008-04-02 | Brystol-Myers Squibb Company | Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof |
| KR101245462B1 (en) | 2005-07-08 | 2013-03-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Sp35 antibodies and uses thereof |
| CN105012953B (en) * | 2005-07-25 | 2018-06-22 | 阿普泰沃研发有限责任公司 | B- cells are reduced with CD37- specificity and CD20- specific binding molecules |
| US20070202512A1 (en) * | 2005-08-19 | 2007-08-30 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| CA2624393C (en) | 2005-11-04 | 2016-01-05 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| JP2009517340A (en) | 2005-11-04 | 2009-04-30 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
| CA2628238A1 (en) | 2005-11-07 | 2007-05-18 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
| US20070136826A1 (en) * | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
| US20090175872A1 (en) | 2005-12-02 | 2009-07-09 | Biogen Idec Ma Inc. | Treatment of Conditions Involving Demyelination |
| CN101351475B (en) * | 2005-12-30 | 2013-05-15 | 默克专利有限公司 | Interleukin-12p40 variants with improved stability |
| EP1966245B1 (en) | 2005-12-30 | 2011-05-18 | Merck Patent GmbH | Anti-cd19 antibodies with reduced immunogenicity |
| PT1981902E (en) | 2006-01-27 | 2015-11-02 | Biogen Ma Inc | Nogo receptor antagonists |
| CA2642532A1 (en) * | 2006-02-16 | 2007-08-23 | Nascent Biologics, Inc. | Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject |
| WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| KR20090010194A (en) | 2006-04-13 | 2009-01-29 | 노바티스 백신즈 앤드 다이아그노스틱스, 인크. | Methods of treating, diagnosing or detecting cancer |
| NZ572561A (en) * | 2006-06-07 | 2012-05-25 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
| CA2654317A1 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| AU2007261247A1 (en) * | 2006-06-22 | 2007-12-27 | Vaccinex, Inc. | Anti-C35 antibodies for treating cancer |
| SI2029173T1 (en) | 2006-06-26 | 2016-12-30 | Macrogenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| MY162024A (en) | 2006-08-28 | 2017-05-31 | La Jolla Inst Allergy & Immunology | Antagonistic human light-specific human monoclonal antibodies |
| BRPI0715660B8 (en) | 2006-09-01 | 2021-05-25 | Zymogenetics Inc | isolated antibody that binds to human IL-31; and, use of a monoclonal antibody |
| CA2957056A1 (en) | 2006-09-06 | 2008-03-13 | C3 Jian, Inc. | Selectively targeted antimicrobial peptides and the use thereof |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| EP2407548A1 (en) | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
| TWI419904B (en) | 2006-12-18 | 2013-12-21 | Genentech Inc | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| EA017611B1 (en) | 2007-01-05 | 2013-01-30 | Юнивэсэти Оф Цюрих | Method for preparing a disorder-associated protein specific binding molecule or an antibody or a binding fragment or at least one immunoglobulin chain, binding said protein (variants), a binding molecule, an antibody, an immunoglobulin chain or a binding fragment thereof (variants), an antigen, a polynucleotide, vector and a host-cell, a composition comprising them and a kit and a method of diagnosing or treating neurological disorders by using said subjects (variants) |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| LT2740744T (en) | 2007-01-09 | 2018-05-10 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
| EA017403B1 (en) | 2007-02-02 | 2012-12-28 | Байоджен Айдек Эмэй Инк. | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation |
| US8846005B2 (en) | 2007-03-14 | 2014-09-30 | Novartis Ag | APCDD1 inhibitors for treating, diagnosing or detecting cancer |
| JP5456658B2 (en) | 2007-03-30 | 2014-04-02 | メディミューン，エルエルシー | Antibody preparation |
| TW200902547A (en) | 2007-04-27 | 2009-01-16 | Genentech Inc | Potent, stable and non-immunosuppressive anti-CD4 antibodies |
| EP2164868B1 (en) | 2007-05-04 | 2015-03-25 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Engineered rabbit antibody variable domains and uses thereof |
| ES2470772T3 (en) | 2007-05-11 | 2014-06-24 | Altor Bioscience Corporation | Fusion molecules and variants of IL-15 |
| NZ583605A (en) | 2007-08-29 | 2012-10-26 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
| EP2205071B1 (en) * | 2007-10-11 | 2015-07-22 | Biogen MA Inc. | Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| JP5754046B2 (en) * | 2007-11-08 | 2015-07-22 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Use of a LINGO-4 antagonist in the treatment of conditions involving demyelination |
| JP2011504371A (en) | 2007-11-21 | 2011-02-10 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Anti-factor XI monoclonal antibody and method of use thereof |
| ES2550757T3 (en) | 2007-12-18 | 2015-11-12 | Bioalliance C.V. | Antibodies that recognize an epitope containing carbohydrates in CD43 and ACE expressed in cancer cells and methods of use thereof |
| AU2008341050B2 (en) | 2007-12-26 | 2013-10-24 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
| EP2388323B1 (en) | 2008-01-11 | 2016-04-13 | Gene Techno Science Co., Ltd. | Humanized anti-9 integrin antibodies and the uses thereof |
| KR20100107501A (en) | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | Cysteine engineered antibodies for site-specific conjugation |
| BR122020023189B1 (en) | 2008-02-08 | 2022-02-01 | Astrazeneca Ab | Use of a pharmaceutical composition comprising an antibody specific for ifnar1 |
| US20110020368A1 (en) | 2008-03-25 | 2011-01-27 | Nancy Hynes | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
| EP2365003A1 (en) | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| CA2720048A1 (en) | 2008-04-16 | 2009-10-22 | Biogen Idec Ma Inc. | Method of isolating biomacromolecules using polyalkylene glycol and transition metals |
| CA2721716C (en) | 2008-04-24 | 2019-09-24 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof |
| CA2729961C (en) | 2008-07-09 | 2018-05-01 | Biogen Idec Ma Inc. | Li113, li62 variant co2, anti-lingo antibodies |
| US8163497B2 (en) | 2008-09-07 | 2012-04-24 | Glyconex Inc. | Anti-extended type I glycosphingolipid antibody, derivatives thereof and use |
| US20120251502A1 (en) | 2008-10-24 | 2012-10-04 | The Government of the US as Represented by the Secretary of the Dept. of health | Human Ebola Virus Species and Compositions and Methods Thereof |
| EP3521309A1 (en) | 2008-12-19 | 2019-08-07 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
| US20100159485A1 (en) * | 2008-12-19 | 2010-06-24 | Centre For Dna Fingerprinting And Diagnostics | Detection of mycobacterium tuberculosis |
| CN102341411A (en) | 2008-12-31 | 2012-02-01 | 比奥根艾迪克Ma公司 | Anti-lymphotoxin antibodies |
| WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| US20110014190A1 (en) | 2009-02-12 | 2011-01-20 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| EP2405920A1 (en) | 2009-03-06 | 2012-01-18 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
| WO2010104208A1 (en) | 2009-03-10 | 2010-09-16 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized k33n monoclonal antibody |
| CN102428103B (en) | 2009-03-24 | 2015-04-08 | 泰华生物制药美国公司 | Humanized antibodies against light and uses thereof |
| EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
| CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| KR20170080705A (en) | 2009-05-08 | 2017-07-10 | 백시넥스 인코포레이티드 | Anti-cd100 antibodies and methods for using the same |
| CN102802661B (en) | 2009-06-22 | 2016-01-13 | 米迪缪尼有限公司 | For the engineered Fc district of site-specific conjugation |
| PL2464664T3 (en) | 2009-08-13 | 2016-02-29 | Crucell Holland Bv | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
| EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
| US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
| WO2011036118A1 (en) | 2009-09-22 | 2011-03-31 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
| US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
| CA2780221A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| WO2011079283A1 (en) * | 2009-12-23 | 2011-06-30 | Bioalliance C.V. | Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same |
| EP2542578A1 (en) | 2010-03-05 | 2013-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Smoc1, tenascin-c and brain cancers |
| US8617557B2 (en) | 2010-03-12 | 2013-12-31 | The Regents Of The University Of California | Antibody fusion with IL-12 proteins with disrupted heparin-binding activity |
| US20130034543A1 (en) | 2010-04-19 | 2013-02-07 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Modulating xrn1 |
| EP2580239A1 (en) | 2010-06-10 | 2013-04-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
| AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
| NZ718973A (en) | 2010-07-09 | 2019-01-25 | Janssen Vaccines & Prevention Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| EP2608807A1 (en) | 2010-08-27 | 2013-07-03 | Stem Centrx, Inc. | Notum protein modulators and methods of use |
| WO2012025636A1 (en) | 2010-08-27 | 2012-03-01 | University Of Zurich | Method for target and drug validation in inflammatory and/or cardiovascular diseases |
| US9963504B2 (en) | 2010-09-02 | 2018-05-08 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
| EP2611464B1 (en) | 2010-09-03 | 2018-04-25 | AbbVie Stemcentrx LLC | Novel modulators and methods of use |
| EP2614080A1 (en) | 2010-09-10 | 2013-07-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| ES2579077T3 (en) | 2010-09-21 | 2016-08-04 | Altor Bioscience Corporation | Soluble multimeric fusion molecules of IL-15 and methods for making and using them |
| ES2686550T3 (en) | 2010-10-11 | 2018-10-18 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
| DK2635607T3 (en) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN |
| EP2640738A1 (en) | 2010-11-15 | 2013-09-25 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Anti-fungal agents |
| SG190990A1 (en) | 2010-12-08 | 2013-07-31 | Stem Centrx Inc | Novel modulators and methods of use |
| MY166537A (en) | 2010-12-14 | 2018-07-10 | Nat Univ Singapore | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof |
| EP2651979B1 (en) | 2010-12-17 | 2019-08-28 | Neurimmune Holding AG | Human anti-sod1 antibodies |
| SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
| AR085911A1 (en) | 2011-03-16 | 2013-11-06 | Sanofi Sa | SAFE THERAPEUTIC DOSE OF A SIMILAR PROTEIN TO AN ANTIBODY WITH VUAL REGION |
| WO2012168259A1 (en) | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
| US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
| US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| TR201815563T4 (en) | 2011-06-23 | 2018-11-21 | Biogen Int Neuroscience Gmbh | Anti-alpha synuclein binding molecules. |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| EP2753697A1 (en) | 2011-09-05 | 2014-07-16 | ETH Zürich | Biosynthetic gene cluster for the production of peptide/protein analogues |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| US20150044208A1 (en) | 2011-09-23 | 2015-02-12 | Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa | Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics |
| KR102434073B1 (en) | 2011-10-11 | 2022-08-18 | 비엘라 바이오, 인크. | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| EP2773667A1 (en) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
| US10598653B2 (en) | 2011-11-01 | 2020-03-24 | Bionomics Inc. | Methods of blocking cancer stem cell growth |
| CA2853951A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Antibodies and methods of treating cancer |
| US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
| CN109897103A (en) | 2011-11-04 | 2019-06-18 | 酵活有限公司 | There is the antibody design of the stabilization heterodimeric of mutation in Fc structural domain |
| EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
| US20140314787A1 (en) | 2011-11-08 | 2014-10-23 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute | Treatment for neurodegenerative diseases |
| JP2015505828A (en) | 2011-12-02 | 2015-02-26 | イーライ リリー アンド カンパニー | Anti-glucagon antibodies and uses thereof |
| JP6483442B2 (en) | 2011-12-05 | 2019-03-13 | エックス−ボディ インコーポレイテッド | PDGF receptor beta-binding polypeptide |
| CA2859755C (en) | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| US20140363448A1 (en) | 2012-01-02 | 2014-12-11 | Novartis Ag | Cdcp1 and breast cancer |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| ES2812849T3 (en) | 2012-02-24 | 2021-03-18 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and procedures for using them |
| US9890213B2 (en) | 2012-03-02 | 2018-02-13 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| AR090352A1 (en) | 2012-03-28 | 2014-11-05 | Sanofi Sa | ANTIBODIES AGAINST BRADICININE B1 RECEIVER LIGANDS |
| US20150266961A1 (en) | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
| EP2847219A1 (en) | 2012-05-07 | 2015-03-18 | Amgen Inc. | Anti-erythropoietin antibodies |
| MX2014013637A (en) | 2012-05-07 | 2015-02-05 | Sanofi Sa | Methods for preventing biofilm formation. |
| CA2872540A1 (en) | 2012-05-10 | 2013-11-14 | Zymeworks Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain |
| EP2849787A4 (en) | 2012-05-14 | 2016-06-15 | Biogen Ma Inc | Lingo-2 antagonists for treatment of conditions involving motor neurons |
| US9844582B2 (en) * | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| IN2014KN02831A (en) | 2012-05-24 | 2015-05-08 | Mountgate Group Ltd | |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| EP2866831A1 (en) | 2012-06-29 | 2015-05-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
| EP2870242A1 (en) | 2012-07-05 | 2015-05-13 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
| WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
| DK2888283T3 (en) | 2012-08-24 | 2018-11-19 | Univ California | ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE |
| MX2015008024A (en) | 2012-12-21 | 2016-08-08 | Biogen Int Neuroscience Gmbh | Human anti-tau antibodies. |
| US9771413B2 (en) | 2012-12-31 | 2017-09-26 | Neurimmune Holding Ag | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
| WO2014137355A1 (en) | 2013-03-08 | 2014-09-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
| KR102207859B1 (en) | 2013-03-15 | 2021-01-27 | 메모리얼 슬로안 케터링 캔서 센터 | High affinity anti-gd2 antibodies |
| CA2906909A1 (en) | 2013-03-15 | 2014-09-18 | Biological Mimetics, Inc. | Immunogenic human rhinovirus (hrv) composition |
| WO2014145254A2 (en) | 2013-03-15 | 2014-09-18 | Sutter West Bay Hospitals | Falz for use as a target for therapies to treat cancer |
| PL2986312T3 (en) | 2013-04-19 | 2022-04-19 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
| ES2891755T3 (en) | 2013-06-06 | 2022-01-31 | Pf Medicament | Anti-C10orf54 antibodies and uses thereof |
| ES2761587T3 (en) | 2013-08-07 | 2020-05-20 | Friedrich Miescher Institute For Biomedical Res | New screening method for the treatment of Friedreich's ataxia |
| UA118267C2 (en) | 2013-08-13 | 2018-12-26 | Санофі | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
| TW201722994A (en) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and uses thereof |
| CN105792836A (en) | 2013-08-28 | 2016-07-20 | 施特姆森特克斯股份有限公司 | Novel SEZ6 modulators and methods of use |
| SG10201803178UA (en) | 2013-10-24 | 2018-05-30 | Astrazeneca Ab | Stable, aqueous antibody formulations |
| JP6870988B2 (en) | 2014-02-24 | 2021-05-19 | セルジーン コーポレイション | How to use cereblon activators for neuronal amplification and treatment of central nervous system disorders |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2015143271A1 (en) | 2014-03-21 | 2015-09-24 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
| CN106536556B (en) | 2014-04-04 | 2020-02-07 | 生态学有限公司 | Humanized antibodies that bind LGR5 |
| US20170267780A1 (en) | 2014-05-16 | 2017-09-21 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
| WO2015198202A1 (en) | 2014-06-23 | 2015-12-30 | Friedrich Miescher Institute For Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
| KR102398246B1 (en) | 2014-06-30 | 2022-05-17 | 알토 바이오사이언스 코포레이션 | Il-15-based molecules and methods of use thereof |
| EP3164129A1 (en) | 2014-07-01 | 2017-05-10 | Friedrich Miescher Institute for Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
| EP4332119A2 (en) | 2014-07-17 | 2024-03-06 | Novo Nordisk A/S | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity |
| EP3172238B1 (en) | 2014-07-23 | 2020-09-23 | Ohio State Innovation Foundation | Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72) |
| US10961298B2 (en) | 2014-08-21 | 2021-03-30 | The Government Of The United States, Represented By The Secretary Of The Army | Monoclonal antibodies for treatment of microbial infections |
| EP3197557A1 (en) | 2014-09-24 | 2017-08-02 | Friedrich Miescher Institute for Biomedical Research | Lats and breast cancer |
| IL278941B (en) | 2014-09-30 | 2022-07-01 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
| CN107108054B (en) | 2014-10-31 | 2020-10-13 | 免疫医疗有限责任公司 | Improved manufacturing method |
| ES2934940T3 (en) | 2014-12-11 | 2023-02-28 | Pf Medicament | Anti-C10orf54 antibodies and uses thereof |
| JP2018504400A (en) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | LINGO-1 antagonist and use for treatment of demyelinating disorders |
| MX2017011194A (en) | 2015-03-03 | 2018-04-10 | Kymab Ltd | Antibodies, uses & methods. |
| KR102618312B1 (en) | 2015-03-17 | 2023-12-28 | 메모리얼 슬로안 케터링 캔서 센터 | Anti-MUC16 antibody and use thereof |
| SG11201707593UA (en) | 2015-03-31 | 2017-10-30 | Medimmune Ltd | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| WO2017048902A1 (en) | 2015-09-15 | 2017-03-23 | Board Of Regents, The University Of Texas System | T-cell receptor (tcr)-binding antibodies and uses thereof |
| EA201890613A1 (en) | 2015-09-21 | 2018-10-31 | Аптево Рисёрч Энд Девелопмент Ллс | POLYPEPTIDES CONNECTING CD3 |
| JP2018535655A (en) | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | ASGR inhibitor |
| WO2017072669A1 (en) | 2015-10-28 | 2017-05-04 | Friedrich Miescher Institute For Biomedical Research | Tenascin-w and biliary tract cancers |
| US20170157215A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| JP7078536B2 (en) | 2016-01-08 | 2022-05-31 | アルトゥルバイオ， インコーポレイテッド | Tetravalent anti-PSGL-1 antibody and its use |
| KR20240017421A (en) | 2016-03-10 | 2024-02-07 | 비엘라 바이오, 인크. | Ilt7 binding molecules and methods of using the same |
| CA3018081A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
| WO2017192697A1 (en) | 2016-05-04 | 2017-11-09 | National Health Research Institutes | Immunogenic peptide containing a b cell epitope of tumor associated antigen l6 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| JP2018035137A (en) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | Novel anti-fibroblast activated protein (FAP) binding agent and use thereof |
| KR102392142B1 (en) | 2016-10-21 | 2022-04-28 | 알토 바이오사이언스 코포레이션 | Mutimeric IL-15-Based Molecules |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| EP3574012A1 (en) | 2017-01-27 | 2019-12-04 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| SG11201909466RA (en) | 2017-05-05 | 2019-11-28 | Vaccinex Inc | Human anti-semaphorin 4d antibody |
| CA3082365A1 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
| JP7165193B2 (en) | 2017-11-27 | 2022-11-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | Humanized antibody targeting human tissue factor |
| JP2021517564A (en) | 2018-03-12 | 2021-07-26 | メモリアル スローン ケタリング キャンサー センター | Bispecific binding factors and their use |
| TWI790370B (en) | 2018-04-02 | 2023-01-21 | 美商必治妥美雅史谷比公司 | Anti-trem-1 antibodies and uses thereof |
| WO2019244107A1 (en) | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
| SG11202108560RA (en) | 2019-02-13 | 2021-09-29 | Brigham & Womens Hospital Inc | Anti-peripheral lymph node addressin antibodies and uses thereof |
| CN113874392A (en) | 2019-03-28 | 2021-12-31 | 丹尼斯科美国公司 | Engineered antibodies |
| JP2022521850A (en) | 2019-04-03 | 2022-04-12 | ジェンザイム・コーポレーション | Anti-alpha beta TCR-binding polypeptide with reduced fragmentation |
| JP2022532928A (en) | 2019-05-24 | 2022-07-20 | サノフイ | Methods for treating systemic scleroderma |
| AU2020289587A1 (en) | 2019-06-07 | 2021-12-23 | Amgen Inc. | Bispecific binding constructs with selectively cleavable linkers |
| WO2021202473A2 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Engineered antibodies |
| WO2021202463A1 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Anti-rsv antibodies |
| WO2021247812A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
| US20230382978A1 (en) | 2020-10-15 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
| WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
| TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
| CN116783217A (en) | 2020-12-03 | 2023-09-19 | 安进公司 | Immunoglobulin constructs with multiple binding domains |
| KR20230146522A (en) | 2021-01-13 | 2023-10-19 | 메모리얼 슬로안 케터링 캔서 센터 | Anti-DLL3 antibody-drug conjugate |
| CA3204628A1 (en) | 2021-01-13 | 2022-07-21 | John T. POIRIER | Antibody-pyrrolobenzodiazepine derivative conjugate |
| EP4294834A2 (en) | 2021-02-19 | 2023-12-27 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Single domain antibodies that neutralize sars-cov-2 |
| WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1564666A (en) * | 1978-05-31 | 1980-04-10 | Ng Mun Hon | Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof |
| GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4935352A (en) * | 1985-10-21 | 1990-06-19 | Takeda Chemical Industries, Ltd. | Expression vector for animal cell line and use thereof |
| US4997913A (en) * | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
| JPH082315B1 (en) * | 1987-05-29 | 1996-01-17 | Sagami Chuo Kagaku Kenkyusho | |
| ATE88900T1 (en) * | 1987-09-02 | 1993-05-15 | Ciba Geigy Ag | INTERFERON ALPHA CONJUGATES WITH IMMUNOGLOBULINS. |
| IL89504A0 (en) * | 1988-03-08 | 1989-09-10 | Univ Wyoming | Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same |
| CA1329119C (en) * | 1988-03-29 | 1994-05-03 | Milton David Goldenberg | Cytotoxic therapy |
| IE62463B1 (en) * | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| KR900005995A (en) * | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
| IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP0433442A4 (en) * | 1989-07-06 | 1992-08-05 | Seragen, Inc. | Hybrid molecules |
| EP0423641A3 (en) * | 1989-10-18 | 1992-01-15 | Nippon Mining Company Limited | Expression vector, transformed microorganism, fusion protein and method for the production of platelet factor 4 or tgfalpha |
| US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
-
1990
- 1990-01-22 US US07/468,390 patent/US5314995A/en not_active Expired - Lifetime
-
1991
- 1991-01-21 ES ES91100695T patent/ES2115596T5/en not_active Expired - Lifetime
- 1991-01-21 AT AT95116766T patent/ATE227776T1/en not_active IP Right Cessation
- 1991-01-21 ES ES95116766T patent/ES2186701T3/en not_active Expired - Lifetime
- 1991-01-21 DK DK91100695T patent/DK0439095T4/en active
- 1991-01-21 AT AT91100695T patent/ATE166232T1/en not_active IP Right Cessation
- 1991-01-21 DK DK95116766T patent/DK0699766T3/en active
- 1991-01-21 DE DE69129421T patent/DE69129421T3/en not_active Expired - Lifetime
- 1991-01-21 DE DE69133148T patent/DE69133148T2/en not_active Expired - Lifetime
- 1991-01-21 EP EP91100695A patent/EP0439095B2/en not_active Expired - Lifetime
- 1991-01-21 EP EP95116766A patent/EP0699766B1/en not_active Expired - Lifetime
- 1991-01-22 CA CA002034741A patent/CA2034741C/en not_active Expired - Lifetime
- 1991-01-22 JP JP21667491A patent/JP3171268B2/en not_active Expired - Lifetime
-
1994
- 1994-05-23 US US08/247,437 patent/US5645835A/en not_active Expired - Lifetime
-
1998
- 1998-08-07 GR GR980401791T patent/GR3027613T3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US5314995A (en) | 1994-05-24 |
| EP0439095B1 (en) | 1998-05-20 |
| EP0439095B2 (en) | 2004-12-15 |
| DE69129421D1 (en) | 1998-06-25 |
| JP3171268B2 (en) | 2001-05-28 |
| ATE227776T1 (en) | 2002-11-15 |
| DK0439095T3 (en) | 1999-01-25 |
| ES2115596T3 (en) | 1998-07-01 |
| ES2186701T3 (en) | 2003-05-16 |
| EP0439095A3 (en) | 1992-01-15 |
| DE69129421T2 (en) | 1999-02-18 |
| CA2034741A1 (en) | 1991-07-23 |
| DE69133148D1 (en) | 2002-12-19 |
| DK0439095T4 (en) | 2005-03-21 |
| ES2115596T5 (en) | 2005-06-16 |
| US5645835A (en) | 1997-07-08 |
| ATE166232T1 (en) | 1998-06-15 |
| DE69129421T3 (en) | 2005-07-21 |
| GR3027613T3 (en) | 1998-11-30 |
| EP0439095A2 (en) | 1991-07-31 |
| JPH0687898A (en) | 1994-03-29 |
| DK0699766T3 (en) | 2003-03-17 |
| DE69133148T2 (en) | 2003-07-24 |
| EP0699766B1 (en) | 2002-11-13 |
| EP0699766A1 (en) | 1996-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2034741C (en) | Therapeutic antibody based fusion proteins | |
| EP1289564B1 (en) | T cell receptor fusions and conjugates and methods of use thereof | |
| US5824782A (en) | Immunoconjugates II | |
| JP3780315B2 (en) | Anti-IL-8 monoclonal antibody for the treatment of inflammatory diseases | |
| Fell et al. | Genetic construction and characterization of a fusion protein consisting of a chimeric F (ab') with specificity for carcinomas and human IL-2. | |
| CA2095836C (en) | Cytokine immunoconjugates | |
| CA2305630C (en) | Soluble single-chain t-cell receptor proteins | |
| AU2001275246A1 (en) | T cell receptor fusions and conjugates and methods of use thereof | |
| AU665360B2 (en) | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis | |
| US20110070191A1 (en) | T cell receptor fusions and conjugates and methods of use there of | |
| SK1842002A3 (en) | A fusion protein, a multi-function protein complex, a multi-function fusion protein, a nucleic acid, a cell, their use, method for preparing a fusion protein and method of targeting cytokines | |
| IE61563B1 (en) | Interleukin-1 receptors | |
| WO1993015766A1 (en) | Desensitization to specific allergens | |
| JPH06506697A (en) | Human PF4A receptor and its use | |
| US5260416A (en) | Antigenic epitopes present on membrane-bound but not secreted IgE | |
| CN111100211B (en) | Fc fusion protein and application thereof | |
| AU625534B2 (en) | Interleukin-1 receptors | |
| JPH0928385A (en) | Dna arrangement of cd23 under soluble state and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |